Investigation of mesenchymal stem cells and the development of experimental strategies for rescuing glaucomatous eyes using a stem cell-based therapy by Ye, Eun-Ah
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2013
Investigation of mesenchymal stem cells and the
development of experimental strategies for rescuing
glaucomatous eyes using a stem cell-based therapy
Eun-Ah Ye
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Cell Biology Commons, and the Neuroscience and Neurobiology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Ye, Eun-Ah, "Investigation of mesenchymal stem cells and the development of experimental strategies for rescuing glaucomatous eyes
using a stem cell-based therapy" (2013). Graduate Theses and Dissertations. 13496.
https://lib.dr.iastate.edu/etd/13496
  
  
Investigation of mesenchymal stem cells and the development of 
experimental strategies for rescuing glaucomatous eyes using a stem 
cell-based therapy 
by 
 
Eun-Ah Ye 
 
A dissertation submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
Major: Neuroscience 
 
Program of Study Committee: 
Donald S. Sakaguchi, Major Professor 
Heather M. Greenlee 
Jeffrey J. Essner 
Srdija Jeftinija 
N. Matthew Ellinwood 
 
Iowa State University  
Ames, Iowa 
2013 
 
Copyright © Eun-Ah Ye, 2013. All rights reserved.
ii 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS………………………………………...……………………..vii 
ABSTRACT ...... ………………………………………………………….……...…… viii 
CHAPTER 1: GENERAL INTRODUCTION ……………………………...…………... 1 
Introduction    …………………………………….……………………..……….. 1 
Dissertation Organization   ………………………………………………….….. .2 
Literature Review  ………………………………………………………………..3 
        Overview  ……………………………………………………….……………......3 
The Mammalian retina  ……………………….….……………………… 4 
             Glaucoma  ……………………………………………………….………. 7 
Animal models of glaucoma  ...………………………………..……….....8 
Genetic model of Glaucoma_DBA/2J mouse ………………..………….10 
Additional genetic Model of Glaucoma_Myocilin (MYOC)-mutant 
mouse……………………………………………………….…...…….…12 
Neurotrophic factors  ………………………………………..…………..14 
Brain derived-neurotrophic factor (BDNF) and Retina …………..……..15 
Glial cell-derived neurotrophic factor (GDNF) and Retina  …….............16 
Neurotrophic factors and Treatment of Retinal Damage ………..….…...17 
Mesenchymal stem cells  ……….………………………..……………...19 
Cellular-based retinal therapies  …….………………..……...………..…21 
Viral constructs  …………………………………..…….…….…….…...22 
Retinal functional measurement ………………..………….…….……...23 
Summary  ………………………………………………………………….….…25 
References ………………………………...….……………………………..…...26 
 
CHAPTER 2: BONE MARROW-DERIVED MESENCHYMAL STEM CELLS 
STIMULATE NEURITE OUTGROWTH FROM ADULT HIPPOCAMPAL 
PROGENITOR CELLS……………………………….…………………………..….….42 
  Abstract  …………………………………………………………………………42 
 iii 
Introduction ………………………………………………………………….…..44 
 Materials and Methods  ……………………………………………………….....45 
   Animals  ………………………………………………..………..………45 
MSC isolation and culturing …………………………………………….46 
            Population doubling time  ……………………………….….…….….…47           
5-bromo-2-deoxyuridine (BrdU) assay  …………………..…..…...……47 
 Propidium iodide (PI) staining ………………………….……….…..….48 
           Adipogenesis ………………………………………………….….….….48 
           Osteogenesis ……………………………………………….…..……..…49 
           Co-Culture of MSCs with AHPCs …………………………….……..…49 
           Immunocytochemistry ……………………………………….……….…50 
           Quantification of neurite outgrowth ………………………..……….…...51 
           Imaging and statistics ……………………………………………….…..51 
 Results  ……………………………………………………………………...…...52 
Isolation and characterization of Brown Norway rat MSCs …….………52 
MSC growth rate and proliferation …………………………...…………53 
Cell Viability ……………………………………………….………..…..54 
Differentiation of MSCs into mesodermal lineages ……….…..………...54 
Co-culture of MSCs with AHPCs ……………….………………..…..…55 
Discussion  ………………………………………….……………………….......57 
Acknowledgments  ………………………………………….…………..…….....63 
References..……..………………………………………………….……..……...63 
Figure Legends…………………………………………………….……….....….68 
Tables and Figures  .…………………………….………………………..……...74 
 
CHAPTER 3: ENGINEERING MOUSE MESENCHYMAL STEM CELLS  
DERIVED FROM BONE MARROW AND IN VITRO CHARACTERIZATION .…....83 
 Abstract  ……………………………………………...…………...……………..83 
Introduction  ……………………………………….………….…….....………...84 
 iv 
  Materials and Methods ………………………………………....………………..86 
   Mouse mesenchymal stem cells …………….…………………………...86 
Engineering mesenchymal stem cells Ex-Vivo with lentiviral vectors….87  
        ELISA of BDNF and GDNF production …………….………………….88 
       Bioactivity assay of neurotrophic factors …………………….………....89 
Immunocytochemistry ………………………….…………….………....90 
Quantitative analysis of neurotrophic factor expression on the MSCs…..91  
Imaging and statistics ...………………………….………..……………..91 
  Results ……………………………………………………………………...……92 
Increased expression of neurotrophic factors in the MSCs. …….………92 
Enhanced secretion of neurotrophic factors from the MSCs……..…...…93 
Bioactivity of neurotrophic factors released from the MSCs……...….…94 
Discussion …………………………….…………………………………………95 
Acknowledgments …………………….…….………………...………………....98 
References …...……………………………………………………………..……98 
Figure Legends………………………………………………………………….104 
Tables and Figures…………………………………….……...………………...107 
 
CHAPTER 4: FUNCTIONAL AND HISTOLOGICAL EVALUATIONS OF THE 
RETINA AND OPTIC NERVE OF DBA/2J MICE AFTER MSC 
TRANSPLANTATION………………………………………………………………...115 
Abstract  ………………………………………………………………………..115 
Introduction ...…………………………………………………………………..117 
Materials and Methods  ………………………………………………………...120 
Animals …………………………………………...…….……………...120 
Mouse mesenchymal stem cells (MSCs) ...……………...….………….121 
Engineering MSCs Ex Vivo with lentiviral vectors……...…………..…121 
Cell transplantation ……………………………………………….……122 
Measurement of intraocular pressure (IOP) ……………………………123 
 v 
Pattern electroretinogram (PERG) ………………………………......…123 
Tissue preparation and immunohistochemistry …….…....……..……...124 
  Quantification of retinal layer thickness ……….……...……………….125 
Retinal imaging and statistics …………………………...……………..126 
  Results  ………………………………………………………………………...126 
 IOP measurement after MSC transplantation …………..…….….……126 
Assessment of functional RGCs ………………………..……………..127 
Survival of transplanted MSCs in adult DBA/2J mice ……..…………128 
Qualitative analysis of retinal structure of the host retinas after MSC 
transplantation..……………………………...……...............................128 
Assessment of retinal layer thickness ……………………….………...129 
Changes of RGC and acetyl-cholinesterase (ChAT)-IR amacrines in  
the host retina.………………….....….……………………………......130 
Discussion ……………………………………………….…..…….…………...130 
References  …..……………………………………………...……………….....135 
Figure Legends…………………………………………….…..………………..138 
Tables and Figures……………………………………….….………………….142 
 
CHAPTER 5: HISTOLOGICAL EVALUATIONS OF RETINAS FROM  
MYOCILIN (MYOC)-MUTANT MICE AFTER MSC TRANSPLANTATION……..152 
Abstract  ……………………………………………………………..…………152 
Introduction ...……………………………………………………..……………153 
Materials and Methods  ……………………………………….…….……….…155 
Animals …………………………………………………….……..……155 
Mouse mesenchymal stem cells (MSCs) ………………………............156 
Engineering MSCs Ex Vivo with lentiviral vectors ………..……..…....156 
Cell transplantation ………………………………………...………..…157 
Tissue preparation and immunohistochemistry ……………...………...158 
RGC counting …………………………………………...…………..…159 
 vi 
Imaging and statistics ………………………………………………..…159 
Results  ……………………………………………………...………….………160 
Long-term survival of MSCs in adult eyes of MYOC-mice  ……...…...160 
Assessment of RGC survival after MSC transplantation  ……...………161 
Expression of myocilin on the ocular tissues  ……………...………..…161 
Discussion  ………………………………………………………..……………162 
References ……..……………………………………………...……….…....….164 
Figure Legends………………………………………………...……….……….167 
Tables and Figures…………………………………….…………..…….….......169 
 
CHAPTER 6: GENERAL CONCLUSIONS  ………………….……..…………….…174 
 
RECOMMENDATIONS FOR FUTURE RESEARCH ………………...………..……176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
ACKNOWLEDGMENTS 
I would like to thank my major professor, Donald Sakaguchi, for his support and 
guidance during my Ph.D. study and research. Besides my major professor, I would like 
to thank the rest of my thesis committee: Dr. Matthew Ellinwood, Dr. Heather Greenlee, 
Dr. Jeffrey Essner, and Dr. Srdija Jeftinija for their help and comments. Also, I appreciate 
my collaborators for their guidance and assistance with these projects, especially Dr. Gil 
Ben-Shlomo, Dr. Matt Harper, and Dr. Kabhilan Mohan for their help with PERG work. I 
thank to all the members of the Sakaguchi lab for their help so far.  
I appreciate my undergrads, especially, Jake Rysted, Sara Adelman, and Rose Perry for 
their help with the histological studies, and Amy Harvey, Pat Poston, Sagar Chawla, and 
Michael Khan for MSC in vitro studies. 
And finally, I am sincerely grateful to my family in Korea for their love, sacrifice, and 
prayer, Sung Kyung Seo and Ka Eun Lee for their spiritual support, without which this 
would not have been possible.  
 
 
 
 
 
 
 
 
 
 
 viii 
ABSTRACT 
 
Glaucoma, the second leading cause of blindness in the world, is a hereditary 
ocular disease and about 60 million people suffer from it [1]. However, currently there 
are no remedies to cure glaucoma. As a potential solution to rescue degenerating retinas, 
stem cells have been investigated extensively and the effects of morphological 
neuroprotection or functional recovery have been reported [2-5].  [5]In the present studies, I 
aimed to investigate two main topics of research. From the first topic, we demonstrated 
MSCs from Brown Norway rats are a self-renewing, multi-potent population. More 
importantly, we provide the first evidence that bone marrow MSCs are capable of 
promoting neurite outgrowth from adult hippocampal progenitor cells (AHPCs).  
For the second topic of research, mouse MSCs were engineered to over-express 
brain-derived neurotrophic factor (BDNF) and/or glial cell-derived neurotrophic factor 
(GDNF) together with green fluorescent protein (GFP), as a strategy for stem cell-based 
therapy. Our results show MSCs, infected with lentiviral vectors encoding BDNF or 
GDNF, noticeably increased the release of bioactive neurotrophic factors in vitro. 
For our in vivo study of stem cell-therapy, two different mouse models of 
experimental glaucoma were studied. MSCs, following intraocular transplantation, 
survived up to 4 months post-transplant (PT) in the host retina of adult DBA/2J mice. 
Interestingly, our results indicated MSCs expressing GDNF played a potential role in 
alleviating glial activation on host retinas. Importantly, our data show GDNF/BDNF-
MSCs contributed to preservation of the inner retina of the recipient eye, compared to the 
control fellow eye.  
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An additional transgenic mouse model of glaucoma, Myocilin (MYOC)-mutant mice, 
was investigated. Our preliminary study showed transplanted MSCs survived up to 11.5 
months-PT in the adult host retina. No significant changes in the number of retinal 
ganglion cells between experimental and control eyes were found at 11.5 months-PT.  
These studies are the first to characterize bone marrow-derived MSCs from 
Brown Norway rats and to study potential neuroprotective effects of transplanted MSCs 
on the host retinas of DBA/2J and MYOC-mice. This study provides an experimental 
strategy towards clinical applications in terms of using MSCs as a potential autograft and 
long-term neuroprotection via neurotrophic factor delivery for retinodegenerative 
diseases.
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CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
Mesenchymal stem cells (MSC) are a potential resource for stem cell therapy, and a 
very attractive, promising candidate for syngeneic transplant. Glaucoma, the second leading 
cause of blindness in the U.S., is a hereditary optic neuropathy. There is no remedy to cure 
the disease, yet. Many studies have been performed to develop therapeutic strategies of 
neurodegenerative ocular diseases. However, there still exist great needs for investigation to 
establish robust resources of stem cells and to develop long-term strategies of stem cell 
therapy. In these series of experiments, I investigated a new line of mesenchymal stem cells 
and therapeutic strategies for stem cell-based therapy on transgenic mouse models of 
experimental glaucoma.   
The hypotheses for this work are: 1) mesenchymal stem cells isolated from the bone marrow 
of Brown Norway rats are self-renewing, multipotent, and capable of stimulating neurite 
outgrowth from neural stem/progenitor cells; and 2) mesenchymal stem cells can be 
engineered to over-express bioactive neurotrophic factors and serve as a potential transplant 
for models of experimental glaucoma.  
A set of specific aims was generated to test the hypotheses. 
Specific Aim I: Isolate and characterize mesenchymal stem cells from the bone marrow of 
Brown Norway rats and investigate the capability of stimulating neurite outgrowth from adult 
hippocampal progenitor cells (AHPCs). 
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Specific Aim II: Engineer mouse mesenchymal stem cells derived from bone marrow and 
perform in vitro characterization.  
Specific Aim III: Perform functional and histological evaluations of the host retina and optic 
nerve of glaucomatous eyes after MSC transplantation. 
Dissertation Organization 
 This dissertation is organized in the alternative format, which includes two 
manuscripts prepared for submission. The manuscripts are organized into three separate 
research chapters. 
 
1. Eun-Ah Ye, Sagar Chawla, Michael Khan, and Donald S. Sakaguchi. Bone marrow-
derived mesenchymal stem cells stimulate neurite outgrowth from adult hippocampal 
progenitor cells. Prepared for submission to Journal of Neuroscience Research. 
 
2. Eun-Ah Ye, Jacob Rysted, and Donald S. Sakaguchi. Long-term strategy of rescuing 
glaucomatous eyes: Transplant of bone marrow-derived mesenchymal stem cells engineered 
for production of neurotrophic factors into the eyes of DBA/2J mice. Prepared for submission 
to Stem Cell Research. 
In addition to the three research chapters, the fourth research chapter presents a 
preliminary study of an additional glaucoma model, the Myocilin transgenic mouse model. 
The final chapter of this dissertation contains general conclusions and recommendations for 
future research with regards to these projects. 
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Literature Review 
Overview 
The central nervous system (CNS), including the retina, plays a pivotal role in the 
body. However, the mammalian CNS lacks regenerative abilities. Therefore, the 
development of therapeutic strategies for neurodegeneration is of great interest. Currently, 
millions of people in the U.S. suffer from ocular diseases, which eventually can lead to vision 
loss. Glaucoma, the second leading cause of blindness in the U.S., is a hereditary ocular 
disease and about four million Americans are affected. At the moment, no remedies to cure 
glaucoma exist and most treatments focus on lowering elevated intraocular pressure (IOP). 
These approaches do not provide neuroprotection on the degenerative eye. Stem cell therapy, 
as a potential treatment for neurodegenerative disorders, has been investigated extensively 
and much evidence showing significant neuroprotection has been reported. Establishing 
reliable and robust resources for stem cell lines are important to provide broader accessibility 
of the usage for research and clinical therapy. Moreover, developing long-term strategies of 
stem cell-based therapy may provide a potent solution to cure challenging, disastrous 
neurological diseases. The results presented within this dissertation focus on 1) 
characterizing a new cell line of rat MSCs as a potential resource for transplantation studies 
in rats and 2) developing long-term strategies of neuroprotection on glaucomatous eyes of 
transgenic mouse models. The resource for this new rat MSC line will be useful not only for 
the development of treatment strategies of glaucomatous eyes, but also for a variety of other 
neurodegenerative conditions. In addition, therapeutic strategies proposed here show 
potential for long-term treatment on glaucoma via the engineered MSCs possible with 
autotransplants. Thus, this study has significance in the clinical setting.   
 4 
The Mammalian retina  
The retina is a light-sensitive tissue lining the back of the eye, 200 µm thickness in 
rodents [6], and is a part of the central 
nervous system. The retina is the first 
region visual processes occur and 
sends the integrated information to 
the targeted areas of the brain via the 
optic nerve.  
Figure 1. Structure of adult human eye. (Citation-http://webvision.med.utah.edu/) 
 
The retina is an excellent model of CNS 
development, due to its relatively simple 
structure.  The retina is developed from the 
anterior neural tube. The anterior neural tube 
develops to form optic vesicle and, subsequently, 
optic cup. The neural retina is formed from the 
inner layer of the optic cup [7, 8].  
Figure 2. Structure of adult human retina. Image from Dr. Donald Sakaguchi; Abbreviations- 
RPE: retinal pigment epithelium, OS: outer segments, ONL: outer nuclear layer, OPL: outer 
plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell 
layer, OFL: optic nerve fiber layer, ILM: inner limiting membrane, C: cones, R: rods, HC: 
horizontal cells, BP: bipolar cells, AC: amacrine cells, RGC: retinal ganglion cells. 
 
All vertebrate retinas have the same structural basis, consisting of seven major classes of 
cells and two major synaptic layers [7]. The developmental processes are highly regulated by 
 5 
intrinsic and extrinsic cues, and vertebrate retina generally follows the same pattern of 
retinogenesis with some variations between species [7].  Retinal ganglion cells are generated 
first, followed by cones, amacrine cells, and horizontal cells. Then, rod photoreceptors are 
formed, followed by bipolar cells, and finally, Müller glia. An overlap in the time points of 
cell birth exists during development. Development of the retina in the mouse begins at 
embryonic day 10 (E10) and is fully developed a few days after birth [7, 8].  
A fully developed retina is a complex neural circuit. All vertebrate retinas consist of 
three nuclear layers and two plexiform layers. Six different classes of neurons make up the 
retina—rods, cones, horizontal cells, bipolar cells, amacrine cells, and retinal ganglion cells. 
In addition, three types of glial cells exist in the retina—Müller glia, astrocytes, and 
microglia [9]. The rod and cone photoreceptors, comprising the outer nuclear layer, are the 
largest populations in the retina and initiate the process of phototransduction. Rod 
photoreceptors outnumber cones by twenty fold in most mammals [10]. The outer plexiform 
layer, the location of the first synapses in the retina, processes the visual information from 
the rods and cones to the second order neurons. Various bipolar and horizontal cells, located 
in the inner nuclear layer, transmit the information from the photoreceptors to the inner 
plexiform layer. The inner plexiform layer is the synaptic region where bipolar, amacrine, 
and retinal ganglion cells interact. Retinal ganglion cells, the final output neurons, receive the 
visual message from the two nuclear layers and send the information to the target areas of the 
brain via optic nerves.  
There are subtypes of each major class of retinal neurons. Mammalian retinas have about 55 
different specific cell types. Retinal cell types are classified based on dendritic morphology, 
the sizes of cell body and dendritic tree, or cell stratification. Two main types of 
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photoreceptor, cones and rods, exist.  There are 9–11 types of cone-bipolar cells and a type of 
rod-bipolar cell, two types of horizontal cells, 29 types of amacrines, and 10-15 types of 
retinal ganglion cells in a typical mammalian retina [10].  
In addition to the neuronal populations, there are three major classes of glial cells in 
the retina. Müller glia, as the principal type of intrinsic macroglia in the retina, provides 
structural support spanning the thickness of the retina, and forming the outer and inner 
limiting membranes. Müller cells elicit cellular depolarization as they express many 
neurotransmitter receptors and voltage-gated channels. Also, they regulate neuronal activity 
by controlling the concentrations of ions and neurotransmitters in the extracellular space [11]. 
Müller cells work as an accelerator for the process of neuronal degeneration, or mediate the 
protection of nerve cells by secreting trophic factors and uptaking excitotoxin glutamate [12]. 
Very interestingly, they play a crucial role in vision by serving as a low-scattering passage 
for light from the innermost layer to the photoreceptors [13].   
The second type of macroglia in the retina are the astrocytes. Astrocytes are primarily 
restricted to the nerve fibre layer and they distribute only in vascularized region. The 
astrocytes migrate from the brain along the optic nerves [14]. Gap junctional coupling 
between retinal astrocytes, between Müller cells, and between astrocytes and Müller cells has 
been reported [15]. Astroglial activities, such as hypertrophy and phagocytosis of dead RGCs, 
are involved in the pathological conditions of retina [16] .  
The third type of glia of the retina are the microglia. These cells are distributed 
broadly in the inner part of retina, mostly locating in the inner plexiform layer and nerve 
fiber layer [17]. Microglia are cells of hemopoietic origin and invade the retina via blood 
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vessels of the optic disc, iris, and ciliary body. Microglia function in host defense against 
foreign microorganisms, and they invade and become activated under pathological conditions 
in the retina [18-20]. It is likely that microglial cells contribute to the regenerative processes 
[21, 22] 
 
Glaucoma  
Glaucoma is a group of ocular diseases and multi-factorial disorders [23]. In the U.S., 
millions of people suffer from ocular diseases, which eventually can lead to vision loss. 
There are 60 million people affected in the world and 8.4 million among them are blind 
bilaterally [1]. Glaucoma is the second leading cause of blindness in the world, and is 
asymptomatic until visual problems occur. It is known that genetic background, as well as 
environmental factors, influences the development of glaucoma. One of the significant 
factors that contribute to glaucoma is elevated intraocular pressure (IOP). Death of retinal 
ganglion cells (RGCs) is the most significant result, causing vision loss.     
There are two major types of glaucoma from which most subjects suffer: (1) open-
angle glaucoma and (2) angle-closure glaucoma [1]. Open-angle glaucoma is characterized 
by the fact that intraocular pressure of the subject is often in the normal range, but associated 
factors, such as stress related to the pressure, contribute to glaucoma. This type of glaucoma 
progresses slowly and is usually asymmetric and bilateral. Genetic background is also 
influential. The ethnic origin of Africans shows a relatively high prevalence of glaucoma [24-
26]. 
Angle-closure glaucoma is categorized by the symptoms of elevated intraocular 
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pressure resulting from obstruction of the outflow of aqueous humor, due to the angle closure 
between the iris and trabecular meshwork. This glaucoma shows progressive and asymmetric 
loss of vision like open-angle glaucoma, but a sudden decrease of visual ability occurs. This 
type of glaucoma is found in one-third of the subjects with primary glaucoma worldwide. 
About twice the number of people with angle-closure glaucoma show vision loss compared 
to those with open-angle glaucoma. Genetic background is also influential in angle-closure 
glaucoma and a known risk factor is small size of the eye. It is known that the ethnic origin 
of Indians and Asians, women, and older individuals have higher risks of developing angle-
closure glaucoma [27]. 
The pathogenesis of glaucoma includes characteristic phenomena. The connective 
tissues at the optic disc are altered and that induces the excavation of the optic cup. This 
occurs coincidently with the early axonal abnormalities [28]. Damaging effects at the optic 
nerve head result in axon injury, and both retrograde and anterograde axonal transport are 
blocked [29]. Primary degeneration of RGCs appears to cause secondary RGC death with a 
harmful environment, resulting from the generation of free radicals [30], glutamate 
excitotoxicity [31], and impaired functioning of immune responses [32]. There are common 
pathways for neuronal degeneration in Alzheimenr’s disease and glaucoma, such as 
deposition of amyloid-beta [33] and decrease of nerve fiber layer (NFL) thickness [34]. 
 
 
Animal models of glaucoma 
Research into neurodegenerative diseases, including glaucoma, is quite extensive. Yet, 
the molecular and physiological mechanisms underlying glaucoma are not completely 
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understood. In vivo studies are essential to reveal the complicated phenomena occurring in 
the organisms. Animal models for glaucoma are required to understand why and how the 
death of retinal cells occur, and to develop new strategies to treat the disease. Currently, there 
are no complete animal models that mimic human glaucoma. Thus, developing a model is 
very challenging and complex work. So far, several models in different species have been 
developed in order to study experimental glaucoma [35]. The monkey has a high homology 
with humans and the anatomy of the eye is almost the same as in human eyes, but monkeys 
are difficult to handle, expensive, and there is limited availability. Three different methods 
have been developed using  the monkey. Argon laser photocoagulation [36]  and diode laser 
photocoagulation [37] induced a moderate increase of intraocular pressure (IOP) and optic 
nerve cupping. Another method, injection of autologous blood cells into the anterior 
chambers resulted in extended IOP elevation [38, 39]. However, it reduced the ability to 
visualize the retina and optic nerve head. Additionally, injection of latex microspheres into 
the anterior chamber induced different durations and levels of IOP elevation. This method 
does not require expensive equipment and does not block the visual field to examine the 
optic disc [40].  
Mice and rats are common models to study ocular diseases and have been extensively 
used. They are easy to handle, relatively inexpensive, and their genome has considerable 
conservation with humans. Also, their lifespan is about two years and they develop diseases 
relatively in a short time frame, compared to humans, who take decades to develop. Mice 
provide even greater availability than rats, since there is a variety of knockout and transgenic 
mice [41] which greatly facilitates investigations into the genes and pathology involved in 
the diseases.  
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In rats, several methods to elevate IOP are currently available [35]. Translimbal laser 
photocoagulation is simple, reproducible, reliable, and produces a sustained elevation of IOP 
[42]; whereas, other methods available are more difficult and time consuming. Cauterization 
of large veins [43, 44], injection of hyperosmotic saline into the episcleral veins [45, 46], and 
injection of India ink into the anterior chamber a week prior to laser photocoagulation [47], 
all induce elevated IOP in the rats. All four of these methods produce acute models of 
experimental glaucoma and sometimes require repetition of the procedure, if the IOP 
difference between experimental and control eyes is not significantly large. In addition to 
these models, magnetic microspheres were used to induce a sustained IOP elevation by 
injecting into the anterior chamber. This method is simple and effective to induce 
experimental glaucoma [48]. Also, polystyrene microbeads injected into the anterior chamber 
caused ocular hypertension [49].  
In mice, both laser photocoagulation and injection of hyperosmotic saline on the 
limbus [35], and polystyrene microbeads [49] work successfully to induce IOP elevation and 
axonal loss. In addition to these acute models of glaucoma, genetic models are also available 
in mice. These are transgenic mice and more suitable for the study of chronic glaucoma 
compared to the acute models. Two major models of transgenic mice are currently available: 
(1) DBA/2J and (2) myocilin-mutant (MYOC) mice. Details about these models are 
discussed in the following sections.    
 
Genetic model of glaucoma_DBA/2J mouse 
The DBA/2J mouse is a hereditary and spontaneous glaucoma model. It is a very 
good tool to study experimental glaucoma, because the mouse model is well-investigated and 
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has characteristics of human glaucoma, including age-related progression of IOP elevation 
and RGC death, and excavation of the optic nerve head [50].  
DBA/2J mouse is an inbred mouse strain and homozygous for both Tyrp1
b
  and 
Gpnmb
R150X 
 mutations [51]. These mutations generate iris diseases in the mice, which are iris 
stromal atrophy and iris pigment dispersion [52]. Iris stromal atrophy is caused by a mutant 
allele of tyrosinase related protein 1 (Tyrp1
b
 ) [51] and has the characteristics of deteriorating 
iris stroma and the blockage of the ocular drainage with stromal cell fragment and pigment 
[52]. Iris pigment dispersion is caused by a mutation in Gpnmb
R150X  
gene and is characterized 
by pigment dispersion and transillumination defects [51, 53]. Two other strains of DBA/2J, 
D2.Tyrp1B6GpnmbB6 and D2-Gpnmb+, were generated by replacing the mutant alleles of 
either both Tyrp1 and Gpnmb or only Gpnmb by wild-type allele. None of the strains showed 
elevated IOP or glaucoma [54].  
Different aspects of glaucomatous phenomena have been investigated on the mouse 
model. DBA/2J mice have shown a linear increase of IOP from 2 to 10 months of age- from 
15~16 to 22~23 mmHg. IOP is correlated with the preservation of the optic nerve, as well as 
corneal thickness [55]. It was also reported that DBA/2J mice showed a progressive decrease 
of pattern electroretinogram (PERG) amplitude after 3 months of age and the amplitude 
reached the noise level by 11 months [56]. In addition, visual performance of DBA/2J mice 
has been studied behaviorally using different types of methods.  
DBA/2J mice showed decreased visual performance in the visual water task starting around 7 
months of age. Optomotor test also showed that the visual acuity of aging DBA/2J mice was 
significantly decreased about 7 months of age.[57].  
In addition, many glaucomatous characteristics of morphological changes in the eyes 
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of DBA/2J mice have been reported. DBA/2J mice show timeline changes of RGCs. The 
deficits in axonal transport, found after age 6 months, precedes axonal loss and cell loss 
(NeuN-IR), observed at about 13- and 18-months old mice, respectively [58]. Another study 
reported that axonal loss and gliosis in the optic nerve are evident in DBA/2J mice around 8 
to 9 months of age. Loss of RGCs, examined by âGeo expression, is apparent about 8 to 10 
months of age and is predominant after 10.5 months of age [59]. A study on DBA2/NNia 
mice reported preferential cell loss of larger RGCs [60], and the other study showed 
topological RGC loss, not cell type-specific, in DBA/2J mice [61]. 
 In addition to the degeneration of RGCs, glial changes in the retina and optic nerve 
are also crucial factors involved in the progression of glaucoma. Increased reactivity on the 
retinal astrocytes and Müller cells, and increased number of microglia were shown in aging 
DBA/2J mice after 3- to 4-months of age [62, 63]. Also, in the optic nerves of aged DBA/2J, 
the loss of oligodendrocytes, proliferation of oligodendrocyte precursor cells, new 
oligodendrocyte generation, an early increase in astrocyte reactivity, and activation of 
microglia were shown [64]. Moreover, correlations between (1) corneal thickness with IOP 
[55], (2) the number of remaining oligodendrocytes and the number of axons, and (3) the 
activation of resident microglia to axon degeneration in the optic nerves [64] have been 
reported.   
 
Additional genetic model of glaucoma_Myocilin (MYOC)-mutant mouse 
 
MYOC-mouse, in addition to the DBA/2J mouse, is an additional chronic model of 
experimental glaucoma. In humans, there is an inheritance factor in primary open-angle 
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glaucoma (POAG) and mutations in MYOC are found in 3-4% of people with POAG [65], 
and more than 70 MYOC mutations have been revealed [66]. Glaucoma associated with 
Myocilin appears to be inherited with autosomal dominant pattern [67, 68]. Mutations in 
MYOC have been referred to as ―glaucoma-causing mutations‖ as they are able to cause the 
development of POAG on their own without influence from the environment or other genes. 
In contrast, glaucoma risk alleles, are another group of mutations and they would cause 
POAG when associated with environment or other alleles [69]. In addition, there are 
differences of ethnicity on MYOC mutations. One of the most common mutations, 
GLN368STOP, has been found in almost all POAG populations including Caucasians and 
African-Americans. However, the mutation has not been detected in Asian patients [65].  
Myocilin contains 504 amino acids [70] and has a molecular weight of about 55–57 
kDa [71]. Initially, it was found that Myocilin is distributed preferentially in the connecting 
cilium of photoreceptors and suggested as a novel cytoskeletal protein playing a role in the 
morphogenesis of photoreceptors [71]. This protein is a secreted glycoprotein that is highly 
expressed in the trabecular meshwork, ciliary body, sclera, and iris, and also expressed in 
retina and optic nerve head at low amounts [72]. More specifically, myocilin was localized in 
the cells of iris stroma, ciliary epithelium, and smooth muscle cells forming the blood vessels 
and iris muscles in the anterior part of the eye [73]. In the trabecular meshwork, cells in the 
corneoscleral and uveal meshwork and also extracellular matrix of the juxtacanalicular region 
express myocilin. These regions are located nearby Schlemm’s canal [74]. It has been 
suggested that myocilin plays a role in the interaction of cell and matrix, but the functions of 
myocilin are not fully understood, yet [65, 72, 75, 76].  
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MYOC-mice, Tg-MYOC
Y437H
, were generated by using a human MYOC gene modified to 
introduce a point mutation. These mice express human MYOC, which contains the mutation 
under the control of the CMV promoter, within ocular tissues including trabecular meshwork 
[77]. It has been reported mutant Myocilin accumulates in the endoplasmic reticulum (ER), 
and results in ER stress and cytotoxicity on the cells of the trabecular meshwork. Such ER 
stress may lead to the development of IOP elevation [77-79]. Tg-MYOC
Y437H
 mice were 
characterized and showed glaucomatous phenotypes, such as IOP elevation, axon 
degeneration, and the death of RGCs [77]. RGC function, measured by pattern 
electroretinogram (PERG), was decreased as the mice aged- 40% in 4 months of age and 
60% in 12 months of age [77]. In addition, Tyr437His mutant mice showed 20% loss of 
RGCs in the peripheral retina at 18 months of age, compared to that of wild-type littermates. 
However, no significant RGC loss was found in the central retina [80]. 
 
Neurotrophic factors 
Neurotrophic factors are secreted proteins and a variety of NFs are expressed 
throughout the nervous system. Neurotrophic factors are significant in therapeutic strategies, 
since they play crucial roles in the survival and neuroprotection of neuronal cells [81-83]. 
Three major families of NFs are especially relevant to glaucoma: (1) NGF-family, (2) GP130 
cytokine, and (3) TGF-beta superfamily [84].  
First, the NGF-family includes brain derived-neurotrophic factor (BDNF), nerve 
growth factor (NGF), and neurotrophin (NT)-3, -4, and -5.  Ligands of the NGF-family bind 
to two different receptors: (1) the tropomyosin receptor kinase (Trk) with high affinity and 
(2) the p75NT receptor with low affinity. BDNF, NT-4 and -5 bind to TrkB, NGF binds to 
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TrkA, and NT-3 binds to TrkC. All ligands bind to the p75NT receptor. When a ligand binds 
to the receptors, downstream signals are activated, such as ERK and mTOR pathways, which 
promote cell survival and growth. However, signals, activated by p75, result in apoptosis via 
the activity of Jun N-terminal kinase (JNK) [85].  
Second, the GP130 cytokine family includes ciliary neurotrophic factor (CNTF), 
interleukin-6, and the leukemia inhibitory factor (LIF). The ligand binds to the receptor 
complex, including GP130, LIF receptor β, and CNTF receptor α. The activation of the 
receptors promotes cell survival via JAK/STAT signaling [86, 87].   
Third, the glial cell-derived neurotrophic factor (GDNF), which belongs to the TGF-beta 
superfamily, also plays a role in promoting cell survival. TGF-beta superfamily members 
activate signaling pathways by binding to specific surface receptors. There are two primary 
types of receptors, type I and type II, which are serine/threonine kinases. Additionally, 
receptor type III lacks the kinase activity and regulates the availability of ligand to type I and 
II [203].  
GDNF binds to the GDNF family receptor alpha (GFRα) to form receptor complexes. 
This receptor complexes signal through the transmembrane RET receptor—tyrosine kinase. 
GDNF binding to a receptor complex activates signaling pathways, such as PI3K and MAP 
kinase [88].   
 
Brain derived-neurotrophic factor (BDNF) and Retina 
BDNF belongs to the NGF family and plays important roles as a mediator of 
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morphological and synaptic plasticity in the brain [89]. It is known BDNF expression is 
localized in the retina, and the RGCs and a subpopulation of cells in the inner nuclear layer 
express BDNF in the mature mouse retina [90]. The expression of TrkB, a BDNF receptor, is 
expressed in the majority of RGCs, amacrines, and at the vitreal border of the inner nuclear 
layer in the vertebrate retina. Also, the expression of p75NTR is observed on the Müller cells. 
The use of neurotrophic factors, such as BDNF, has gained considerable interest for 
developing strategies for rescuing injured/or degenerating retinas. It is known that retrograde 
transport of BDNF is interrupted in eyes of experimental glaucoma [91, 92]. Previous studies 
showed exogenous BDNF prolonged the survival of cultured RGCs [93-95], stimulated 
regrowth of RGC axons [96], and increased the survival of RGCs [5, 97] in vivo. Especially, 
BDNF delivered via MSCs to glaucomatous eyes with chronic ocular hypertension provided 
both functional and structural neuroprotection on the host retina and optic nerve [5]. 
While IOP elevation may interrupt the retrograde transport of BDNF in glaucomatous 
retinas, endogenous sources within the retina may provide a balance of the expression in the 
eye. In the retinas of DBA/2J mice, an experimental glaucoma model, the expression of 
BDNF increases as they age. The elevated IOP induced the expression of BDNF on the 
Müller glia, while the nerve fiber layer and astrocytes are the locations where heavily 
concentrated BDNF is observed at all ages [Calkins DS, ARVO 2010]. However, complex 
pathways involved in BDNF and its receptors—TrkB receptor, truncated TrkB receptor, and 
p75NT receptor—are not fully understood, and further investigation is required to understand 
their molecular physiology.  
 
Glial cell-derived neurotrophic factor and retina 
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Glial cell-derived neurotrophic factor (GDNF) belongs to the transforming growth 
factor (TGF)-beta superfamily and is a glycosylated homodimer [98]. GDNF binds to the 
GDNF family receptor alpha (GFRα), a cell surface receptor, to form receptor complexes that 
signals through the transmembrane RET receptor—tyrosine kinase [88]. Both GFRα and 
RET receptors were identified on the RGCs, amacrine, and horizontal cells in embryonic 
chick retina [99]. GDNF binding activates signaling pathways, which include mitogen-
activated protein (MAP) kinase, phosphoinositide (PI)-3-kinase, phospholipase C Ɣ (PLC-Ɣ), 
and Src-family kinases [88].  
GDNF was first isolated from a rat glial cell line and showed the ability to increase 
the survival of dopaminergic neurons [98]. GDNF is expressed in response to neuronal injury 
and during retinal development [100-102].  
It has been shown that GDNF is secreted by astrocytes [103] and GDNF-receptors are 
expressed on the RGCs, amacrines, and horizontal cells [99]. As GDNF receptors, Ret is 
expressed in horizontal, amacrine, or RGCs and not in photoreceptors or Müller cells. 
GFRα1 expression is found in horizontal, amacrine, and RGCs, GFRα2 is localized in 
amacrine and RGCs, in the mouse retina. GDNF, like BDNF, is another potent survival 
factor, since it has been reported to enhance neuronal survival in vitro [104], as well as in 
vivo showing promise for the therapy of neurodegenerative disorders or damage [81, 105-
108].   
 
Neurotrophic factors and treatment of retinal damage  
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Elevated IOP is one of the most significant risk factors contributing to glaucoma, and 
RGC death is a major problem causing irreversible vision loss. It has been reported that 
ocular hypertension contributes to the deprivation of NFs by blocking retrograde transport 
[91, 92]. Thus, several kinds of experimental approaches to deliver NFs have been performed 
thus far. Fibroblast growth factor (FGF) promoted the survival of retinal ganglion cells after 
optic nerve injury [109, 110]. In addition, administration of purified BDNF [111], ciliary 
neurotrophic factor (CNTF) [112], and nerve growth factor (NGF) [113] into the eyes of 
animals with ocular hypertension reduced RGC loss. However, this approach has a limitation 
that requires repetitive administration of the NFs for long-term protection. Another approach 
to NF delivery is biodegradable NF-microspheres and gene therapy application. Studies using 
microspheres manufactured to release GDNF have shown protective effects on the RGCs of 
degenerating retinas [108, 114, 115]. This method also has shortcomings—burst release or 
inconsistent speed of release of NF and the release lasts for a relatively short period of time. 
Gene therapy, another method, using adenoviruses or adeno-associated viruses (AAVs), 
which encode BDNF [116, 117], GDNF [118], or  CNTF [119, 120], has shown a potency to 
increase RGC survival in animal models of optic nerve transection/or ocular hypertension. 
This approach has drawbacks, such as immunogenicity of the vectors and toxicity in the host. 
As an alternative to these limitations discussed above, using stem cells as a cellular vehicle 
for NF delivery has been suggested and investigated. Previous studies showed bone marrow-
derived MSCs, injected into the vitreous cavity, exerted neuroprotective effects on the RGC 
axons in a rat glaucoma model [4]. In addition, MSCs, engineered to express BDNF, rescued 
degenerating retinas structurally, as well as functionally [5]. In addition to MSCs, it has been 
reported that Schwann cells enhanced the survival of RGCs or stimulated axonal regeneration 
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[121-124], as they produce a variety of neurotrophic factors, cell adhesion molecules, and 
extracellular matrix, and also they stabilize the elongating axons by utilizing focal tight 
junctions [125].  
The combination of different neurotrophic factors also have been applied and rescued 
injured or degenerating retinal neurons.  Combined injection of BDNF and neurturin as well 
as BDNF and GDNF showed additive effects on the RGC survival after optic nerve 
transection. Also, administration of GDNF along with neurturin showed an increased effect 
on the survival of RGCs [126]. Treatment of basic fibroblast growth factor (bFGF) and 
epidermal growth factors (EGF) alone enhanced photoreceptor survival in vitro, though there 
was no synergistic effect when combined [127]. The combination of BDNF with CNTF also 
promoted the survival of rd (retinal degeneration) photoreceptors more effectively than the 
treatment of either BDNF or CNTF in explants [128]. We suggest that stable and sustained 
delivery of neurotrophic factors, such as GDNF and BDNF, using a cellular vehicle would be 
an ideal strategy for long-term neuroprotection to degenerating retina.  
 
Mesenchymal stem cells  
Mesenchymal stem cells (MSCs), also called multipotent stromal cells, have the 
ability to self-renew and differentiate into various mesodermal lineages, such as bone, 
cartilage, and fat cells [129]. Bone marrow-MSCs can be easily isolated, due to the 
characteristic of plastic-adherence. For several decades, bone marrow-derived MSCs have 
been used in numerous studies, as a potential candidate to develop therapeutic strategies on 
various diseases [130-136]. More importantly, bone marrow-MSCs are a potential candidate 
for autologous transplantation, which avoids immune response in the host. In addition to 
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bone marrow, mesenchymal stem cells have been isolated from a variety of regions, such as 
fetal pancreas [137], liver [138], umbilical cord blood [139], scalp tissue [140], fetal thymus 
[141], bone and adipose tissue [142], vermiform appendix [143], placenta [144], and 
endometrium [145].  
Bone marrow-derived MSCs are a potential cellular source for stem cell-based 
therapy, since they have several advantages, including: (1) easy isolation, (2) significant 
plasticity, (3) no ethical concerns, (4) a potential autologous transplant, and (5) availability of 
engineering to produce a cellular vehicle for delivering NFs for a long-term period.  
Thus, using bone marrow for MSC isolation is a more feasible approach in clinical 
fields. Many human patients have been treated with bone marrow therapy so far [146, 147]. 
However, more studies and investigations on MSC research are still needed for further 
clinical applications.  
Bone marrow-MSCs isolated from different rat strains—Fisher, Lewis, Sprague-
Dawley and Wistar—have been characterized [148]. However, MSCs from the bone marrow 
of Brown Norway rats (Rattus norvegicus) have not been studied systematically with 
defining categories. The Brown Norway rat is an inbred rat strain and one of the animal 
models well-defined genetically, as well as physiologically. Also, the strain has been used in 
a variety of research fields. Nonetheless, to our knowledge there are no established resources 
and studies characterizing bone marrow-derived MSCs from Brown Norway rats. Thus, 
isolation and systematic examinations of MSCs from this strain are required to broaden the 
availability of cell lines for autologous or syngeneic transplant to develop experimental 
strategies for neurodegeneration.  
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Cellular-based retinal therapies 
 
The eye is an immune privileged site [149, 150] and provides tolerant environments 
for cell transplant, minimizing the risk of immune rejection. Thus, the eye is a more suitable 
region for the application of cell-based therapy compared to other body parts, where the 
immune system is active in response to foreign materials. Cell-based therapy has been 
developed widely and recognized as very promising for the cure of degenerative retinal 
diseases. Currently, the available approaches for cell-based therapy can be categorized into 
two major strategies—cell replacement and neuroprotection—investigated by cell 
transplantation. 
A variety of cell sources have been developed and investigated to rescue degenerating 
retinas in vivo. Human embryonic stem cell-derived retinal pigment epithelium (RPE), 
transplanted into the subretinal region of a Royal College of Surgeons rat, improved visual 
performance [151]. In addition, differentiated human fetal RPE [152], brain stem cells [153], 
bone marrow–derived stem cells [2, 4, 154, 155], retinal stem cells [156, 157], Schwann cells 
and fibroblast [78], retinal sheet [158, 159], and induced pluripotent stem cells (iPSCs) [160-
162] have been used in vivo studies. All showed rescue effects to some extent. However, 
none of these studies provided sufficient evidence for long-term survival of transplant, 
complete retinal integration, and morphological preservation, as well as the functional 
restoration of the host retina for a long-time period.  
Stem cells have been extensively investigated and proposed as a powerful source of 
cell transplantation, due to the capacity of self-renewal and multi-potency. Mesenchymal 
stem cells (MSCs), among a variety of types of stem cells, possess great advantages for 
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success in cell-based therapy. They are robust, proliferate well by providing large quantities 
of cells, differentiate into multiple lineages of cell types [129], survive well in the host retina, 
release trophic factors, contain immunomodulatory functions, and are a potential candidate 
for autologous transplant [129, 163-166].    
Previous studies showed bone marrow-derived MSCs injected into the vitreous cavity 
exerted neuroprotective effects on the RGC axons in a rat glaucoma model [4]. MSCs have 
shown morphological neuroprotective effects on the survival of RGCs/or their axons 
following intravitreal transplantation into the glaucomatous eyes [3, 4]. Supplying 
neurotrophic factors to the retina in acute or chronic models of glaucoma have shown a 
potential approach to protect damaged retinas [108, 114, 119]. As a vehicle to deliver 
neurotrophic factors into the retina, mesenchymal stem cells (MSCs) could play an effective 
role in the eyes with experimental glaucoma. In addition, MSCs, engineered to express 
BDNF, rescued degenerating retinas structurally, as well as functionally [5]. 
 
Viral constructs 
The use of viral vectors is a very powerful approach to deliver genes of interest into 
cells or tissues. Viral vectors, including lentivirus, recombinant adenovirus, and adeno-
associated virus (AAV), possess high efficiency to deliver the gene. Therefore, they are 
commonly used for gene therapy [167-171].  
The lentiviral vector (LV) is a potent and efficient construct to deliver genes into 
nondividing and dividing cells. Also, lentiviral constructs are a self-inactivating vector, 
possess the capability to integrate into the genome of host cells, and result in sustained 
expression of the transgene [172-174]. Lentiviral vectors have been studied for use in gene 
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therapy for the retina [175-182]. It was shown that gene transfer was successful as a 
transducer for both retinal pigment epithelium and photoreceptors in the eyes [170].  
Gene transfer via lentiviral vectors protected retinal degeneration in the rat model of 
Retinitis pigmentosa [179] and preserved cone function in the mouse model of Leber 
congenital amaurosis [181]. Also, the survival of injured RGCs was enhanced in rats with 
axotomy after injection of LVs expressing ciliary neurotrophic factor (CNTF) [180]. 
However, concerns exist with applications of these vectors, due to low efficiency of viral 
infection to mature retinal neurons in vivo [183] and transient toxicity on the retinas [184], 
when used directly into the eyes.  
Lentiviral vectors that delivers BDNF or GDNF genes have been developed also and 
used for the studies of neural repair. BDNF gene transfer via lentiviruses provided 
neuroprotection in a model of excitotoxicity [204] and showed potential rescue effects on an 
injured spinal cord [205]. Delivery of the GDNF gene is  also neuroprotective on a model of 
Parkinson's disease [208], lesioned motorneurons [207], and excitotoxicity [206].   
To overcome the limitations stated above, lentiviral vectors, instead, can be used to 
infect stem cells ex vivo for cell-based therapy [185]. These constructs are a very powerful 
and desirable vehicle to deliver genes into the cells, since they have excellent efficiency for 
cell infection and can be manufactured on a large scale for use in therapeutic treatments [186].      
 
Retinal functional measurement 
Pattern electroretignogram (PERG) is a non-invasive method that allows assessment 
of visual eye function. Patterned light stimuli, which consist of black and white 
checkerboards or gratings, are provided at a constant luminance. The retinal activity, in 
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response to the stimuli, is noted by a recording electrode lying on the surface of the cornea 
[187]. The source of response signals originates from the retina’s RGCs. Patterned gratings 
produce lateral inhibition mediated by horizontal cells. This causes differential activation of 
the dendritic field on RGCs, resulting in the local activity of RGCs summed at the recording 
electrode. Since the retinal potential measured by PERG is driven by cones, focal, and post-
receptoral, the amplitude detected is very small, compared to the conventional ERG [187]. 
The retinal potential of PERG is displayed as a waveform, which consists of an initial 
negative component (N), followed by a positive peak (P), and another large negative 
component (N). For humans, each component is indicated as N35, P50, and N95, 
respectively, reflecting their latency. The amplitude between peaks and troughs is measured 
for functional evaluation, in general [188].  
The usefulness of PERG, as a tool to monitor the dysfunction of RGCs in DBA/2J 
mice, was demonstrated [189]. DBA/2J mice showed a progressive decrease of PERG 
amplitude after 3 months of age and the amplitude reached the noise level by 11 months [56]. 
It has been reported that conventional full-field ERG is not significantly affected by inner 
retinal dysfunction on the DBA/2J mice [189]. 
Different from PERG, conventional ERG utilizes a bright flash of light to obtain a 
response from all retinal neurons. Typical ERG traces include different wave components. 
The a-wave indicates the function of photoreceptors in the outer nuclear layer [190]. The b-
wave indicates the function of inner retinal neurons. Oscillatory potentials, included in the b-
wave, indicates the activity between the neurons of INL and RGCs [191]. The usefulness of 
ERG has been demonstrated on evaluating retinal ischemia [191].   
In addition to these ERG measurements, pupillary light reflex (PLR) can be used to 
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evaluate retinal and optic nerve function. Light stimuli elicit PLR that induces iris 
constriction and change of pupil diameter in response to the light. The reflex pathway begins 
with retina, the signal then travels from the retina to optic nerve, Edinger-Westphal and 
pretectal olivary nuclei, and ciliary ganglion via oculomotor nerve, in sequence. Lastly, 
ciliary nerve leaving the ciliary ganglion constricts the iris muscle.  Pupillary light reflex is 
mediated by intrinsic photosensitive retinal ganglion cells (ipRGCs) which contain 
photopigment, melanopsin. As, such this non-image-forming visual response is independent 
of rod and cone photoreceptors [192, 193]. Pupillometry has been utilized to characterize 
healthy eyes of rat and mouse [194, 195] and showed significant defects in hypertensive eyes 
[196, 197] and in ischemic retina [198]. In addition, pupillometry has been used to evaluate 
functional rescue after ocular transplant to a rat model of photoreceptor degeneration [199], 
and used as a clinical examination of glaucoma [200-202].  
 
 
Summary 
Mesenchymal stem cells are a potential candidate for autologous transplants and is of 
great significance in clinical therapies. Investigating stem cell-based therapy to develop 
neuroprotective strategies is essential to rescue a neurodegenerative eye, since there are no 
remedies to cure glaucoma and stem cells have been shown to be powerful to save 
degenerating retinas morphologically and functionally. The studies discussed in this 
dissertation provide evidence of a new MSC line, isolated from the Brown Norway rat, for 
identification of bona fide MSCs and potency as therapeutic resources. In addition, we assess 
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the potential effects of engineered MSCs, as allografts, on two different transgenic mouse 
models of glaucoma using intraocular transplantation of the MSCs.  
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Abstract 
Bone marrow-derived mesenchymal stem cells (MSCs) have recently emerged as 
beneficial cellular vehicles for nervous system rescue and repair. A better understanding how 
MSCs are involved in mediating neural repair will facilitate development of novel 
therapeutic strategies. Mesenchymal stem cells are ideal candidates for cell-based therapies 
because of their ease of isolation, capacity of self-renewal and phenotypic plasticity. There is 
an increasing need for additional studies of MSCs since they are a potent cell source for cell 
transplants to overcome many diseases. Variations exist on MSC characteristics between 
different strains, and little has been studied in regards to bone marrow-MSCs from Brown 
Norway rats. In the present study we aimed to isolate and characterize bone marrow-MSCs 
from this strain, and more importantly we studied the capacity of MSCs to influence the 
differentiation of adult hippocampal progenitor cells (AHPCs). These MSCs have been 
subcultured up to 20 passages and they showed stable and consistent growth rate. MSCs were 
identified using a panel of phenotypic markers that are positive/or negative to rat MSC. 
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MSCs retained short population doubling time (PDT) and showed very high proportions of 
BrdU-incorporation, an indicator of proliferative cells. In addition, MSCs showed good cell 
viability, evaluated by propidium iodide (PI) staining, and possess the capacity of multipotent 
differentiation (adipogenesis and osteogenesis). We also found endogenous expression of a 
neural marker, nestin, in a small proportion of the MSCs.  In order to explore the potency of 
MSCs to promote regeneration and repair of nervous systems, we examined whether contact 
co-culture (CCC) of MSCs influences AHPC differentiation. Our results revealed that MSCs 
did not significantly affect the proportions of proliferation and neuronal-/and glial-lineage of 
AHPC differentiation. However, both CCC and non-contact co-culture (NCCC) significantly 
promoted neurite outgrowth on neuronal AHPCs and also notably increased branching 
processes on oligodendrocytic AHPCs.   
Our study indicates that the MSCs are a new useful resource for stem cell research, 
including therapeutic applications as a syngeneic transplant to Brown Norway rats. More 
interestingly, the ability of MSCs to promote morphological differentiation on neuronal and 
oligodendrocytic AHPCs would be another attractive value to develop strategies for cell-
based therapies to rescue degenerative nervous systems.   
 
Keywords Brown Norway rat, bone marrow-mesenchymal stem cells, growth, viability, 
multipotent differentiation, co-culture with AHPCs, neurite outgrowth  
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Introduction 
Mesenchymal stem cells (MSCs) have become an important cell source for treatment 
of neurodegenerative conditions as well as nerve repair strategies. Gaining a better 
understanding of how MSCs mediate neural repair will benefit the development of novel 
therapeutic strategies [1-7]. Multipotent MSCs have the ability to self-renew and can 
differentiate into various mesodermal lineages such as bone, cartilage, and fat cells [8]. Bone 
marrow-derived MSCs can be readily isolated due to their characteristic adherence to tissue 
culture plastic surfaces. Importantly, bone marrow-MSCs are a potential candidate for 
autologous transplantation, thus avoiding an immune response in the host. In addition to bone 
marrow, mesenchymal stem cells have been isolated from a variety of tissues such as fetal 
pancreas [9], liver [10], umbilical cord blood [11], scalp tissue [12], fetal thymus [13], 
adipose tissue [14], vermiform appendix [15], placenta [16], and endometrium [17]. 
However, MSC isolation from bone marrow is a relatively common procedure and is 
clinically relevant [18, 19].  
Bone marrow-MSCs isolated from different rat strains- Fisher, Lewis, Sprague-
Dawley and Wistar- have been well characterized [20]. However, MSCs from the bone 
marrow of Brown Norway rats (Rattus norvegicus), have not been studied systematically. 
Brown Norway rats are a relatively common animal model used for biomedical research. 
They are well-defined genetically, physiologically, and behaviorally [21-26]. There are, to 
our knowledge, no established resources and studies performed on bone marrow-MSCs from 
Brown Norway rats. Thus, the isolation and systematic examination of MSCs from this strain 
is required to broaden the availability of cell lines for autologous or syngeneic transplants for 
further development of experimental strategies for neurodegeneration.  
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In this study we have characterized bone marrow-MSCs from Brown Norway rats. 
Three criteria were used to define the MSCs; 1) adherence to tissue culture plastic, 2) 
expression of specific surface antigens, and 3) multipotent differentiation potential [27]. In 
addition to the characterization of MSCs, we also examined the cell growth, proliferation, 
and viability of MSCs. To gain a better understanding of the ability of MSCs to promote 
regeneration and repair of the nervous system, we investigated whether MSCs have the 
capacity to stimulate neurite outgrowth from adult rat hippocampal progenitor cells 
(AHPCs). In this study we demonstrate that MSCs isolated from the bone marrow of Brown 
Norway rats are a pure MSC population and capable of differentiating into adipogenic and 
osteogenic lineages. The MSCs showed consistent cell growth and proliferation, as well as 
good viability through long periods of subculture. Moreover, we demonstrated the capability 
of MSCs to promote neurite outgrowth from TuJ1-IR AHPCs and to enhance 
oligodendrocytic differentiation of AHPCs. These results provide additional support for the 
use of MSCs is a potent resource for the development of strategies for cell-based therapies to 
rescue degenerating nervous systems.    
 
Materials and Methods 
Animals 
Male and female Brown Norway rats, obtained from Charles River Labs, at 6 weeks 
of age were used for the isolation of bone marrow. The animals were kept in a constant 
environment (temperature: 22°C; humidity: 20 %; 14/10-hour light-dark cycle) with food and 
water provided ad libitum until bone marrow was isolated. The rats were allowed to rest for 
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at least 7 days after arrival from the supplier to let them recover from transportation and 
adapt to the new environment before harvesting of bone marrow. All animal procedures for 
this study adhered to the provisions of the Association for Research in Vision and 
Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision 
Research, and had the approval of the Iowa State University Institutional Animal Care and 
Use Committee, and were performed in accordance with committee guidelines. 
 
MSC isolation and culturing 
The rats were euthanized with isoflurane and then the femora and tibiae were 
dissected. These bones were placed in a 50 ml conical tube filled with ice-cold culture media 
[(CM; alpha minimum essential medium (αMEM; Gibco BRL, Gaithersburg, MD) 
supplemented with 20 % fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 4 mM 
L-glutamine (Gibco BRL, Gaithersburg, MD), and antibiotic-antimycotic (Invitrogen, 
Carlsbad, CA)]. For each bone, epiphyses were removed and the marrow was forced out into 
a fresh 150 mm culture dish using a syringe and 23-gauge needle filled with 3 ml CM. The 
marrow suspension was expelled onto a 70 µm filter pre-wetted with CM and transferred into 
a T75 flask with 20 ml CM. The cell suspension was maintained in a culture incubator (37C, 
5% CO2 / 95% humidified air atmosphere). 48 hours after harvest, spindle-shaped cells 
adhered to the flask and media was changed with fresh CM after washing with phosphate-
buffered saline (PBS; Gibco BRL, Gaithersburg, MD ). MSCs isolated from male and female 
rats were cultured separately as different cell lines. MSCs were fed with CM twice a week. 
When the MSCs were about 80 % confluent, subculturing was performed.   
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Population doubling time 
To evaluate the growth of MSCs, we calculated population doubling time (PDT) 
using the formula PDT = 2 ⅹ t ⅹ Ni/No (t: the time required to reach 80% confluency, hr; 
Ni: the initial number of cells; No: the final number of cells) [28]. MSCs at passages 1, 4, 9, 
and 15 were investigated (N=3).  
 
5-bromo-2-deoxyuridine (BrdU) assay 
The proliferation of MSCs was evaluated by incorporation of BrdU (5-bromo-2-
deoxyuridine) into the cells at several passages that correspond to that of the PDT analysis, 
(i.e. passages 1, 4, 9, and 15). MSCs were plated onto 12 mm cleaned glass coverslips at 
approximately 30% confluency with maintenance media (MM), and the following day BrdU 
solution was added (5 µM BrdU in MM). After 24 hours, MSCs were fixed in 4% 
paraformaldehyde in 0.1 M PO4 buffer, pH 7.4. Fixed cells were then rinsed in PBS (137 mM 
NaCl, 2.68 mM KCl, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4) and incubated in 2N 
HCl for 15 min followed by 0.1 M sodium borate solution (pH 8.5) for 5 min. After washing 
with PBS, MSCs were incubated in blocking solution [5% normal donkey serum, 1% bovine 
serum albumin (BSA; Sigma), and 0.1% Triton X-100 (Fisher Scientific) in PBS] for 90 
minutes. A primary antibody (see Table 1) against BrdU was used. To identify cells that 
incorporated BrdU, MSCs were incubated in primary antibody overnight at 4C in a humid 
chamber, washed in PBS, and incubated in Cy3-conjugated secondary antibody for 1.5 hours 
in the dark. The cells were then rinsed and nuclei stained with 4’, 6-diamidino-2-
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phenylindole, dilactate (DAPI, 1:2,000). Preparations were mounted on glass slides with 
Vectashield mounting media (Vector laboratories, Burlingame, CA).  
 
  Propidium iodide (PI) staining 
To investigate the viability of MSCs, PI (Invitrogen, Carlsbad, CA; final 
concentration 1.5 µM) was added to the culture dishes in the dark for 20 min, at 37
o
C. Cells 
were then fixed in 4% paraformaldehyde in 0.1 M PO4 buffer, pH 7.4 and stained with DAPI. 
As a positive control, a group of cells were incubated with 70% ethanol for 2 minutes and 
incubated with PI in the same conditions. Under this control condition all MSCs were PI-
labeled. 
 
Adipogenesis 
A mesenchymal stem cell Adipogenesis kit (Cat. No. SCR 020; Millipore, Billerica, 
MA) was used to generate adipocytes from the isolated rat MSCs. The induction protocol as 
specified in the datasheet was applied. Briefly, MSCs were plated at a density of 60,000 cells 
per well in a 24-well culture plate. When the cells were 100 % confluent, adipogenesis 
induction medium was added into the wells. Induction/and maintenance medium was 
changed every two days for 21 days. MSC cultures were fixed in 4% paraformaldehyde in 
0.1 M PO4 (pH 7.4) for 30 minutes at room temperature and rinsed. Oil Red O Solution was 
added for 50 min to stain adipocytes containing lipid droplets. Cell nuclei were stained with 
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hematoxylin solution incubating for 15 minutes. Astrocytes subjected to the same conditions 
were used as a negative control.  
 
Osteogenesis  
MSCs were induced to differentiate into osteogenic lineages. A mesenchymal stem 
cell Osteogenesis kit (Cat. No. SCR 028; Millipore) was used for induction as per the 
protocol specified in the datasheet provided. Briefly, each well of a 24-well plate was coated 
with vitronectin and collagen in 1X PBS to yield a final concentration of 12 μg/mL for each 
ECM molecule and MSCs plated at a density of 60,000 cells per well. When the cells were 
100 % confluent, osteogenesis induction medium was added into the wells. Induction 
medium was changed every 2~3 days for 14 days. Osteocytes were fixed in iced cold 70% 
ethanol for 1 hour at room temperature. Alizarin Red Solution was added for 30 minutes in 
order to stain osteocytes containing calcium deposits. Astrocytes subjected to the same 
conditions were used as a negative control.  
 
Co-Culture of MSCs with AHPCs 
Adult hippocampal progenitor cells (AHPCs, provided by F. Gage, Salk Institute, La 
Jolla, CA), originally isolated from the brains of adult Fischer 344 rats as reported by Palmer 
and colleagues [29], were used to perform co-culture with MSCs. The culture groups 
consisted of 1) AHPC only, 2) MSC only, 3) Contact co-culture (CCC), and 4) Non-contact 
co-culture (NCCC) of AHPCs with MSCs. First, MSCs were plated on the glass coverslips 
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coated with poly-L-ornithine (100 µg/ml in sterile water) and laminin (10 µg/ml in Earle's 
Balanced Salt Solution (EBSS) (PS-LAM substrates) at an initial density of 7,000 cells per 
well of 6 well culture plate. For the NCCC, we used 0.4 µm semi-porous membrane inserts 
(Corning,Inc., Corning, NY) to separate the MSCs from AHPCs cultured on the surface of 6 
well culture plate. The membrane inserts were placed inside the well and then filled with co-
culture media. Then, MSCs were plated onto the insert well of the plate. The following day, 
AHPCs were plated onto the same culture plate at 20,000 cells per well. The co-cultures were 
maintained in a mixed medium, co-culture media, consisting of AHPC differentiation media 
in a 7:3 mixture with MSC growth media (with 10% FBS) (referred to as co-culture media). 
As controls, AHPCs and MSCs were plated in the same co-culture medium at the same 
density. Cells were maintained at 37
o
C in a 5% CO2/95% air atmosphere in culture medium. 
After 7 days culture, the cells were fixed and immunostained as described in the following 
immunocytochemistry section. 
 
Immunocytochemistry 
To characterize MSCs, we performed immunocytochemistry with a panel of cell-
type specific antibodies. A Rat Mesenchymal Stem Cell Characterization kit (Cat. No. 
SCR018; Millipore) was also used for analysis. For immunolabeling, MSCs were fixed in 4% 
paraformaldehyde in 0.1 M PO4 buffer, pH 7.4. Fixed cells were incubated in blocking 
solution containing 5% normal donkey serum, 0.4% bovine serum albumin (BSA; Sigma), 
and 0.2% Triton X-100 (Fisher Scientific), followed by incubation with primary antibodies 
overnight at 4°C. Primary antibodies and their dilutions are listed in Table 1. After rinsing in 
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PBS, cells were incubated in the secondary antibodies conjugated to Cy3 diluted at 1:500 
(Jackson ImmunoResearch, West Grove, PA). Cell nuclei were stained with 4’, 6-diamidino-
2-phenylindole, dilactate (DAPI), diluted at 1:2,000 in PBS and applied for 30 minutes. 
Preparations were rinsed and then mounted onto microscope slides using an antifade 
mounting medium (Gel Mount; Biomeda Corp., Foster City, CA). Negative controls were 
performed in parallel by omission of the primary antibodies. No antibody labeling was 
observed in the controls.  
 
Quantification of neurite outgrowth 
To perform a quantitative analysis on the neurite outgrowth of AHPCs, we assessed 
the number of neurite branches on TuJ1-immunoreactive (TuJ1-IR) AHPCs. The extent of 
neurite arborization was measured using a Sholl analysis [30, 31] plugin to NIH ImageJ. The 
concentric circles plugin was used to aid in the Sholl analysis by drawing concentric circles 
around the cell. Three concentric circles with radii 10, 20, and 30 µm from the center of the 
cell soma were drawn. The number of intersections between the circles and neurites were 
then manually counted. Analysis was performed in masked fashion. 
 
Imaging and statistics 
Phase contrast images were taken using a Nikon Diaphot inverted microscope with a 
CCD camera (Megaplus; Model 1.4; Kodak Corp., San Diego, CA) connected to a frame 
grabber (Megagrabber; Perceptics, Knoxville, TN, in a Macintosh computer; Apple 
Computer, Cupertino, CA) using NIH Image 1.58VDM software (Wayne Rasband, National 
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Institutes of Health, Bethesda, MD). Images of MSCs labeled with the antibodies were 
captured using an upright fluorescence microscope (Nikon Microphot FXA) equipped with a 
Retiga 2000R digital camera controlled by QCapture software (QImaging, Surrey, British 
Columbia, Canada). Figure plates were prepared using Photoshop CS2. Data were reported 
as means ± S.E.M. Statistical analysis was performed using GraphPad PRISM (ver. 3.0). All 
tests were two-tailed tests and P values less than an alpha of 0.05 were considered 
significantly different.  
 
Results  
Isolation and characterization of Brown Norway rat MSCs 
Culture of MSCs: Mesenchymal stem cells (MSCs) from male and female Brown 
Norway rats were isolated from the bone marrow by the characteristic of adhering to a plastic 
culture surface. The adherent MSCs were cultured as a monolayer and passaged when they 
reached 70~80% confluency. As illustrated in Figure 1, the MSCs showed a typical spindle-
shape and fibroblast-like morphology. At early passage, small and slender MSCs were 
predominantly observed in the population. At later passages, we observed a relatively larger 
ratio of cells with large and flattened morphology compared to that of early passage cells 
(Fig. 1).    
 
Characterization of MSCs: Characterization of the bone marrow-derived cells was 
performed by immunocytochemistry with rat MSC-specific antibody markers. A panel of 
negative and positive antibodies for rat MSCs was used (Table 1). After culturing for 4 or 5 
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passages, the vast majority of the adherent bone marrow-derived cells were specifically 
labeled with antibody markers for MSCs (CD29, CD51, CD54, CD90, fibronectin, and 
collagen type I) (Fig. 2A - F). Furthermore, no MSCs showed specific immunoreactivity for 
the negative markers (CD11b, CD14, CD44, and CD45) (Fig. 2G-J). (See also 
Supplementary Fig. 1. for the characterization of female MSCs.)  
In addition to the screening with MSC-specific markers, we also examined the 
populations with neural markers to examine potential expression of endogenous neural-
lineage markers. About 30% of MSCs were nestin-IR (Suppl. Fig. 2.) and no specific staining 
was found for TuJ1, MAP2ab, or GFAP antibodies (Images not shown).  
 
MSC growth rate and proliferation 
To investigate the growth of MSCs quantitatively, we assessed population doubling 
time (PDT) for the MSCs isolated from both the male and female rats. The growth and 
proliferation of MSCs were analyzed at passages 1, 4, 9, and 15 (Table 2). MSCs from 
female rats (♀) showed values of PDT (hr), 23.74 (± 7.712), 37.01 (± 4.925), 25.76 (± 
7.072), and 28.73 (± 7.743) at P1, 4, 9, and 15, respectively. MSCs from male rats (♂) also 
had a similar range of growth rates with that of MSCs (♀); 17.68 (± 4.137), 29.67 (± 2.164), 
25.5 (± 2.629), and 23.43 (± 2.563) at P1, 4, 9, and 15, respectively. There were no 
significant differences between the different passages/or between MSCs, isolated from male 
versus female Brown Norway rats (P value > 0.05). In addition, a BrdU assay was performed 
to examine the proliferation of MSCs with increasing passage number (Table 3). MSCs were 
exposed to 5 µM BrdU for 24 hours. More than 80% of MSCs were BrdU-immunoreactive 
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(IR) at most passages. A significantly lower percentage (54.76%) of BrdU-labeled cells was 
observed for the MSCs (♂) at P4, although the BrdU percentages were essentially equal 
between the MSC populations at all other time points.    
 
Cell Viability 
To investigate the viability of MSCs while maintained in culture, we performed a 
cell viability staining assay using propidium iodide (PI), a DNA-binding probe. Because of 
the permeability of PI to cells with compromised membrane integrity, we can differentiate 
unhealthy or dead cells from healthy and viable cells by the fluorescence of PI which binds to 
DNA in the nucleus. PI was added directly to the culture dishes with final a concentration 1.5 
µM for 20 min. MSCs maintained under normal growth conditions were not labeled by the PI 
(0% PI-labeled, Supp. Fig. 4A, N=3). However, PI-bound MSCs were shown as a positive 
control (100% PI-labeled following ethanol treatment; Suppl. Fig 3B; N=3). 
 
Differentiation of MSCs into mesodermal lineages 
The multipotential nature of the MSCs was investigated by examining their ability to 
differentiate into adipogenic and osteogenic lineages. MSCs differentiated into adipocytes 21 
days after adipogenic induction. Lipid droplets in adipocytes derived from MSCs following 
induction were stained with Oil Red O solution (Fig. 3. A and A’).  
MSCs subjected to osteogenic induction conditions for 14 days were visualized with 
Alizarin red solution. Amorphous deposits of calcium were stained red, demonstrating 
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osteogenic differentiation ability of the MSCs (Fig. 3. B and B’). For both differentiation 
paradigms (adipogenic and osteogenic) astrocytes were used as a negative control and were 
subjected to the induction protocols and resulted in no Oil Red O or Alizarin red staining, 
respectively (Suppl. Fig. 4. A’’ and B’’). Taken together, these results indicate that we have 
successfully isolated populations of multipotent Brown Norway rat bone marrow-derived 
MSCs. 
 
Co-culture of MSCs with AHPCs  
To examine the possibility that MSCs can influence the proliferation and 
differentiation of adult neural progenitor cells, we established co-cultures of adult 
hippocampal progenitor cells (AHPCs) with MSCs. To delineate possible contact-mediated 
and/or soluble inducing activities associated with the MSCs, the AHPCs were differentiated 
in parallel under three different culture conditions: (1) AHPCs cultured alone, (2) AHPCs 
cultured with MSCs in noncontact co-culture conditions (NCCC), and (3) AHPCs co-
cultured in physical contact with the MSCs (contact co-culture condition, CCC). The AHPCs 
express green fluorescent protein (GFP) which facilitated their identification when co-
cultured with the non-GFP-expressing MSCs (Fig. 4). After 7 days, cultures were fixed and 
immunostained to examine cell proliferation (BrdU-IR) and differentiation. A BrdU analysis 
revealed no significant differences in the overall percentages of AHPCs immunoreactive for 
the BrdU antibody (P value ＞ 0.05; Table 4.). To investigate differentiation, the percentages 
of AHPCs immunoreactive for neuronal (TuJ1-IR) or oligodendrocyte (RIP-IR) markers was 
determined. When cultured alone, ~21% of the AHPCs were TuJ1-IR and ~59% RIP-IR 
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(Table 4.). When co-cultured with MSCs under noncontact conditions (NCCC) ~23% of the 
AHPCs were TuJ1-IR and ~29% RIP-IR. When AHPCs were co-cultured in physical contact 
(CCC) with MSCs ~19% were TuJ1-IR and ~55% RIP-IR. No significant differences in 
AHPC differentiation into TuJ1-IR neurons was observed across the three culture conditions. 
Although the percentage of AHPCs immunolabeled for RIP was on average lower in the 
NCCC condition, there was no significant difference on the percentages between the culture 
groups (P value ＞ 0.05; Table 4.).  
Morphologically we noted discernable differences on TuJ1- and RIP-IR AHPCs in 
both of the co-culture groups (CCC and NCCC) when compared to the AHPCs cultured 
alone. Co-culture with MSCs stimulated neurite outgrowth of neuronal AHPCs (TuJ1-IR). 
TuJ1-IR AHPCs, in both NCCC and CCC conditions, showed longer and highly branched 
neurites when compared to the AHPC only condition (Fig. 5.). Quantitative assessment was 
performed by Sholl analysis as illustrated in Figure 5D. There were significant differences in 
the number of intersections at a radius of 20 µm (AHPC only vs. NCCC and AHPC only vs. 
CCC; P value < 0.05). These results indicate that MSCs and or MSC-derived factors played a 
significant role in the morphological differentiation of AHPCs by promoting neurite 
outgrowth during the co-culture conditions. Furthermore, physical contact (CCC) between 
the MSCs and AHPCs during co-culture resulted in thicker neuronal processes and increased 
complexity, compared to that of the NCCC. In addition to influencing neurite outgrowth 
from TuJ1-IR cells, MSC co-cultures also resulted in more highly branched RIP-IR cells.  
However, we could only analyze the morphology of RIP-IR AHPCs qualitatively, because 
the processes of RIP-IR cells were usually too close or overlapping to be distinguishable 
from those of adjacent cells. Both in NCCC and CCC conditions, RIP-IR cells showed more 
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highly branched morphologies and a larger area of processes than that of the AHPC only 
group. In addition, the thickness of primary processes in CCC group appeared to be thicker 
after co-culture, compared to those of the other groups (Indicated with an arrow head; Fig 6.).  
   
Discussion 
Bone marrow-derived MSCs possess considerable potential towards development of 
cell-based therapeutic strategies. The present study isolated and characterized bone marrow-
derived MSCs isolated from male and female Brown Norway rats (♂ and ♀), a commonly 
used strain for biomedical research [32-37].   MSCs were successfully isolated from the bone 
marrow and were cultured for 20 passages displaying stable and consistent growth rates. 
Immunostaining with a panel of MSC positive- and negative- antibody markers demonstrated 
that the identity of these populations of cells are consistent with MSCs, lacking 
hematopoietic cell lineages. The PDTs for these MSCs was about a day, indicating a 
relatively rapid cell proliferation rate. Furthermore, BrdU assay indicated that most MSCs 
maintained a proliferative capacity throughout the passages examined. When maintained 
under optimal growth conditions, cell viability was high, with little PI staining indicative of 
cell death. In addition, the multipotential nature of these MSCs was demonstrated based on 
their ability for adipogenesis and osteogenesis. The isolation and characterization of these 
Brown Norway rat MSCs will broaden the availability of MSC lines for autologous and 
syngeneic transplants towards development of experimental strategies for treating 
neurodegenerative conditions. 
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When co-cultured with adult hippocampal progenitor cells (AHPCs), the MSCs 
provided significant stimulation of neurite outgrowth. The MSC-associated activity is in part 
likely mediated via soluble cues.    
The Brown Norway rat MSCs isolated and characterized in this study initially were a 
somewhat heterogenous population showing typical morphologies, consisting of spindle-
shaped and fibroblast-like cells as reported previously [42]. The fibroblastic cell morphology 
became more prominent over time upon continued subculturing. The morphological 
characteristics of these MSCs are consistent with other rodent strains of MSCs [20, 28, 41].  
Cell phenotyping was conducted using a panel of MSC positive- (fibronectin, 
collagen type I, CD29, CD54, CD51, and CD90) and negative- (CD11b, CD14, CD44, and 
CD45) antibodies for rat MSCs. In all experiments the MSCs were immunoreactive for the 
positive markers and no detectable immunolabeling for the negative MSC markers was 
observed, suggesting that the population lacked of hematopoietic lineage cells, consistent 
with a highly pure population of MSCs.      
The growth and proliferation of MSCs were studied and compared between cells 
isolated from male and female donor rats to examine the possibility of intrastrain sex 
differences. With increasing passages, MSCs showed some variability in population doubling 
time (18 - 37 PDT (hours)) though the average PDTs were not significantly different from 
early to late passages. Furthermore, no significant differences of PDTs were found between 
male- and female-MSCs as well as between early and late passages. The results of BrdU 
assay also suggest that most MSCs were in actively replicating state. This property would be 
a benefit to meet the needs of generating a large number of cells for scientific research and 
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preclinical applications. Unexpectedly, a low percentage of BrdU-IR cells was observed at 
P4 (♂). Previous studies reported reduced proliferation and/or growth-arrest in rat MSCs at 
passage 4 or 5 [43-45]. Population doubling time at P4 (♂) in the present study, however, 
was not significantly different from other passages and only the ratio of BrdU-IR cells 
decreased. A possible reason may be that a larger proportion of MSCs may linger in G2, M, 
or G0 phases compared to cells at other passages. It is also possible that the time window of 
BrdU exposure for the MSCs was somewhat narrow at P4 (i.e. MSCs were exposed to BrdU 
for 24 hours during 5 days culture (t=5 at P4 (♂); PDT = 2ⅹt ⅹNi/No) at P4). This could 
possibly result in limited incorporation of BrdU into the sub-population in S phase during 
this period. The PDT value of these Brown Norway rat MSCs was relatively short compared 
to those of other strains of rat (Fisher, Lewis, Sprague-Dawley, and Wistar) which showed 
approximately 2-4 days PDT [20]. However, consistent with our data, Karaoz and colleagues 
[28] reported 19-41 hours PDT for Wistar rat MSCs. Nonetheless, it is clear that growth 
characteristics of MSCs, in fact, can vary depending on the species, strains, passages, and the 
regions from which cells were isolated [11, 41, 46] . It is possible that such differences may 
be due to animal age, techniques used for cell isolation and culture, as well as general health 
conditions between individual animals.  
The multipotential ability of these MSCs was demonstrated by their differentiation 
potential into mesodermal lineages. Following the appropriate induction protocols, the MSCs 
had the ability to differentiate into adipocytes and osteocytes in vitro. A growing body of 
literature indicates that MSCs possess phenotypic plasticity and are able to generate 
myoblasts, tendon/ligament fibroblasts, adipocytes, osteocytes, and chondrocytes [8]. Karaoz 
et al. [28] demonstrated endogenous expression of osteo-, myo-, and neuro-genic markers, 
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which supports the plasticity of rat MSCs to differentiate into various kinds of cell types. A 
small proportion of Brown Norway rat MSCs were immunolabeled with a nestin antibody, a 
neural stem cell marker. A complex filamentous network of immunolabeling was observed in 
these MSCs, consistent with nestin intermediate filament labeling. Nevertheless, the ability 
of MSCs to transdifferentiate into neural cells remains a complicated and controversial issue 
requiring additional studies [75, 76].   
A clearly emerging theme for use of MSCs as cellular vehicles for neural repair is 
their neurogenic and neuroprotective activities. MSCs have the ability to synthesize and 
secrete a variety of biomolecules such as neurotrophic factors, cytokines, and growth factors 
[47, 48]. A number of studies have demonstrated that such factors can enhance neural cell 
proliferation, differentiation, and survival [49-55]. Furthermore, MSCs have been shown to 
secrete neurogenic factors including brain-derived neurotrophic factor (BDNF), glial cell 
line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and 
neurotrophin-3 (NT-3). [47, 56, 57]. In the present study, we investigated the ability of these 
MSCs to influence the differentiation of adult rat hippocampus derived progenitor cells 
(AHPCs). These multipotent AHPCs are capable of differentiating into neurons, 
oligodendrocytes and astrocytes [58-60]. Two types of co-cultures were established to exam 
cell-cell associated activities, as well as secreted soluble factors from the MSCs. No 
significant differences in the proportion of AHPC differentiation towards a neuronal (TuJ1-
IR) or glial (RIP-IR) cell type were observed in the co-cultures of MSCs with the AHPCs. 
However, morphological differentiation of both neuronal and oligodendrocyte-like AHPCs 
was evident. Both co-culture configurations (NCCC and CCC) resulted in significant 
increases in neurite outgrowth and complexity on neuronal AHPCs (TuJ1-IR cells) when 
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compared to AHPCs differentiating on their own. We found the expression of TrkB, a 
receptor for BDNF, on AHPCs (data not shown). This would support our results, i.e. 
increased neurite outgrowth from AHPCs when co-cultured with MSCs. We, therefore, 
presume that bioactive BDNF secreted from MSCs binds to TrkB receptors to stimulate 
neurite outgrowth of neuronal AHPCs.  Neurotrophic factors such as BDNF induce neurite 
outgrowth from neuronal cells and neural progenitors [61, 62]. MSCs also express a variety 
of neuro-regulatory molecules, including neurite-inducing factors and axon guidance 
molecules [77]. Further studies will be required to examine what other types of receptors for 
biomolecules are expressed on AHPCs. Interestingly, when co-cultured in direct contact with 
the MSCs (CCC) the AHPCs displayed even more increased complexity of neurites than that 
of NCCC. Thus, it is likely that cell-cell interactions mediated by cell adhesion molecules 
and/or extracellular matrix molecules (ECM) also play important roles in the MSC neurite 
outgrowth promoting activity [63-66]. In the present study, we showed that the expression of 
ECM molecules (fibronectin and collagen type I) and CD29 (integrin β1) on MSCs. It is well-
known that fibronectin and collagen type I interact with integrin α5β1 and α2β1, respectively 
[67]. Moreover, our previous study reported the expression of integrins (α2, α5, and β1) and 
ECM molecules (fibronectin and laminin) on the rat adult brain progenitors [60]. Thus, it is 
possible that physical contact between MSCs and AHPCs would allow cellular interactions 
mediated through integrin-ECM signaling to stimulate neurite outgrowth. Interactions 
between the ECM and integrins activate signaling pathways that modulate the dynamics of 
the cytoskeletons [68], and the changes of cytoskeletal proteins involved in microtubule and 
actin filaments contribute to the formation and regulation of neurite outgrowth [69-71].  
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MSCs possess considerable therapeutic potential due to a number of advantages, 
including relative ease of isolation, plasticity, proliferative capacity, various sources for 
isolation, and differentiation potential into multiple lineages. Clinical studies using human 
bone marrow-mesenchymal cells as allografts have demonstrated practical use of MSCs for 
tissue-repair [18, 19]. MSCs can directly or indirectly affect the outcome after transplantation 
in vivo because of their ability to secrete various factors such as angiogenic, anti-apoptotic, 
proliferation-stimulating factors, and neurotrophic factors [47, 48, 72]. Such utility for MSCs 
has also been suggested by MSC transplantation into the eyes of experimental glaucoma 
models followed by subsequent neuroprotective effects on the retinas [73]. MSCs, 
furthermore, can be genetically modified to express bioactive molecules so they can act as a 
delivery vehicle for the factors in vivo. BDNF-secreting MSCs transplanted into 
neurodegenerative eyes provided notable preservation of the host retinas morphologically 
and functionally [74].  
Our study indicates that MSCs from Brown Norway rats have a potential to be a cell 
source for stem cell-based therapies due to their fast and consistent proliferation, and ability 
for multipotent differentiation. In addition, our MSC line provides an additional choice for 
rat strain as well as stem cell line, which are important factors to develop strategies for a stem 
cell-based therapy. More importantly, we provide the first evidence that bone marrow MSCs 
are capable of promoting neurite outgrowth from adult hippocampal progenitor cells 
(AHPCs). This would be another intriguing value for MSCs to be utilized for rescuing 
injured or degenerating nervous systems.      
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Figure Legends  
Table 1. Antibodies used in this study.  
 
Table 2. Population doubling time (PDT) for MSCs at different passages compared between 
male- and female-MSCs. To study the growth of BN-MSCs, PDT was calculated at different 
passages- 1, 4, 9, and 15- for both male and female MSC populations. PDT values, in 
general, have a range between 18-37 hours. There were no significant differences between 
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the different passages/or between MSCs, isolated from male versus female Brown Norway 
rats. (P value > 0.05). (Sample size; N=3)  
 
Table 3. BrdU assay. MSCs were incubated with BrdU (final concentration 5 µM) for 24 
hours and immunolabeled with a BrdU antibody to investigate the proliferation rate. At all 
passages, more than 80% of MSCs were BrdU-positive, except P4 (♂). BrdU percentage of 
male MSCs at P4 showed a significant difference, compared to that of both male and female 
MSCs at all the passages examined (P value ＜ 0.05; Sample size N=3).  
The results indicate that the majority of the MSCs were in an actively dividing state 
throughout the passages examined.  
 
Table 4. Percentages of differentiating AHPCs after co-culture with MSCs. 
AHPCs were cultured with MSCs for 7 days to study whether co-culture influences the ratio 
of the differentiation of AHPCs. Three different conditions were tested: 1) AHPC only, 2) 
NCCC, and 3) CCC. No significant differences between groups were found for the 
percentages of TuJ1-, RIP-, and BrdU-IR cells (P value ＞ 0.05). Three independent 
experiments were done for the analysis (N=3). Value= Mean % ± S.E.M. Abbreviations- 
AHPC: adult hippocampal progenitor cells; NCCC: non-contact co-culture; CCC: contact co-
culture. 
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Fig 1. (A) Phase contrast images of MSCs (male) at initial isolation (Passage 1, P1) and after 
10 passages (P10). MSCs isolated from BN-rat bone marrow were cultured as a monolayer 
on plastic culture plates. Both small, rapidly self-renewing MSCs and larger, more mature 
MSCs were observed. MSCs had a spindle-shape and fibroblast-like morphology. In later 
passages, a greater proportion of cells displayed a flattened, fibroblast-like morphology. 
Scale bar=200 µm. 
 
Fig 2. Characterization of MSCs immunostained with a panel of phenotypic markers.  
(A - F) Bone marrow-derived cells stained with a panel of MSC specific -positive antibody 
markers. No specific staining with MSC negative antibodies (CD11b, CD14, CD44, and 
CD45) was detected. (CD14- present on leukocytes; CD44- present on leukocytes and 
endothelial cells; CD45- present on monocytes and macrophages). (K and L) No staining was 
found with mouse- and rabbit-IgG antibodies, negative controls. Scale bar= 50 µm (A 
through L).  
Fig 3. Differentiation of MSCs- Adipogenesis and osteogenesis. 
(A - A’) MSCs were cultured in adipogenic induction media for 21 days. Adipocytes 
differentiated from MSCs were stained with Oil Red O Solution. Lipid droplets in adipocytes 
were cleary observed. Cell nuclei were stained with Hematoxylin solution. (B - B’) For 
osteogenesis, MSCs were differentiated in osteogenic induction media for 14 days. 
Osteocytes containing calcium deposits were visualized with Alizarin Red Solution. (Scale 
bars- A and B: 300 µm; A’: 100 µm ; B’: 200 µm)  
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Figure 4. Contact Co-culture (CCC) of AHPCs with MSCs. AHPCs were co-cultured in 
physical contact with the MSCs. An image shown here is contact co-culture condition, CCC. 
The AHPCs, which were expressing GFP, could be identified from the non-GFP-expressing 
MSCs. Image was captured at 3 DIV of co-culture. Scale bar= 50 µm. 
 
Figure 5. Sholl analysis for the quantification of neurite outgrowth of TuJ1-immunoreactive 
AHPCs. 
AHPCs, after 7 days co-culture with MSCs, were immunostained with a neuronal marker 
(TuJ1). Two representative images from each group are presented, from AHPC only (A, A’), 
NCCC (B, B’), and CCC (C, C’) groups. Sholl analysis was performed to measure the extent 
of neurite growth and branching from TuJ1-IR cells. Tthree concentric circles (radii 10, 20, 
and 30 µm from the center of the cell soma) were superimposed onto TuJ1-IR cells. The 
number of neurite intersections with each concentric circle was counted. AHPCs in both 
NCCC and CCC conditions displayed increased neurite outgrowth compared to that of 
AHPC only group.  
D. Neurite complexity summary bargraph.  Neurite outgrowth of AHPCs after co-culture 
with MSCs. Neurite outgrowth of neuronal AHPCs (TuJ1-IR) was quantified by performing 
Sholl analysis. After 7 days co-culture with MSCs, there were significantly increased number 
of neurite intersections at a radius of 20 µm (AHPC only vs. NCCC and AHPC only vs. 
CCC). Error bars= S.E.M.; *: P value < 0.05. 
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Figure 6. Oligodendrocyte differentiation of AHPCs following co-culture with MSCs. 
AHPCs were co-cultured with MSCs for 7 days and immunostained with a oligodendrocyte 
marker, RIP. Nuclei were stained with DAPI. AHPCs in both NCCC and CCC conditions 
showed a more highly branched morphology and in general, a larger area of processes than 
that of the AHPC only group. Also, in CCC condition, the thickness of primary processes 
was generally found to be greater than that of other groups (Indicated with an arrow head). 
Scale bar=50 µm. 
 
Supplementary Fig 1. Characterization of rat bone marrow-derived cells isolated from female 
(♀) Brown Norway rats immunostained with a panel of MSC positive antibodies.  
(A-F) Cells were immunostained with a panel of MSC-positive markers; CD54, CD90, 
fibronectin, collagen type I, CD29, and CD51. No specific staining was found with MSC-
negative markers. Scale bar= 50 µm (Applied from A through F).  
 
Supplementary Fig 2. Endogenous expression of a neural marker 
MSCs were immunostained with a neural marker, nestin, without neural induction. About 30 
% of MSCs were nestin-IR, showing specific filamentous staining pattern in the cells. Nuclei 
were stained with DAPI. Scale bar=50 µm. 
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Supplementary Fig 3. Propidium iodide (PI) staining. To test the viability of MSCs, the cells 
were incubated with propidium iodide (final concentration 1.5 µM) which identifies dead 
cells in a population due to the permeability of PI to cells with compromised membrane 
integrity. (A) No PI-positive cells were found in the population of MSCs maintained in 
normal culture conditions. (B) PI control condition: MSCs incubated with 70% ethanol prior 
to PI incubation were all positively labeled by the PI staining. Images shown were merged 
(DAPI + PI). Repetitive experiments were performed on PI staining. (Scale bar=100 µm; 
Sample size N=3) 
 
Supplementary Fig 4. Differentiation of MSCs (♀)- Adipogenesis and osteogenesis.  
(A - A’) MSCs were cultured in adipogenic induction media for 21 days. Adipocytes 
differentiated from MSCs were stained with Oil Red O Solution. Lipid droplets in adipocytes 
were cleary observed. Cell nuclei were stained with Hematoxylin solution. (A‖) Astrocytes 
served as a negative control for MSC adipogenesis and showed no staining after being 
subjected to the adipogenic induction conditions. (B - B’) For osteogenesis, MSCs were 
differentiated in osteogenic induction media for 14 days. Osteocytes containing calcium 
deposits were visualized with Alizarin Red Solution. (B‖) Astrocytes served as a negative 
control for MSC osteogenesis and showed no staining after being subjected to the osteogenic 
induction conditions. Scale bars- A and B: 300 µm; A’ - A’’: 100 µm ; B’ - B’’: 200 µm. 
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Tables and Figures 
Table 1. Primary antibodies used in this study 
Antibody Species Source (clone) Dilution 
MSC markers       
Fibronectin Rabbit Millipore 1:1,500 
Collagen type I Rabbit Millipore 1:500 
CD 29  
(Integrin beta1) 
Rabbit Millipore 1:500 
CD 51 
(Integrin alpha V) 
Rabbit 
Dr. Thomas Joos, 
NMI, University of Tuebingen   
1:200 
CD90 
(Thy-1.1) 
Mouse 
Dr. Alan F. Williams,  
University of Oxford 
1:200 
CD54 
(ICAM-1) 
Mouse Millipore 1:100 
CD11b Mouse Millipore   1:100  
CD45 Mouse Millipore   1:100 
CD14 Mouse Millipore 1:1,000 
CD44 
(Hermes-1) 
Rat 
Developmental Studies  
Hybridoma Bank (DSHB) 
1:200 
Mouse IgG Mouse Millipore 1:100 
Rabbit IgG Rabbit Millipore 1:500 
Proliferation marker    
BrdU Rat DAKO Corp. 1:100 
Neural markers       
Nestin Mouse  DSHB 1:200 
III β-tubulin (TuJ1) Mouse R&D systems 1:200 
MAP2ab Mouse            Sigma 1:200 
GFAP Mouse Fisher Scientific 1:500 
RIP Mouse DSHB 1:1,000 
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Table 2. 
PDT (hrs)   P1 P4 P9 P15 
MSC (♀) Mean 23.74 37.01 25.76 28.73 
  ± S.E.M. 7.712 4.925 7.072 7.743 
MSC (♂) Mean 17.68 29.67 25.5 23.43 
  ± S.E.M. 4.137 2.164 2.629 2.563 
 
 
Table 3. 
% BrdU   P1 P4 P9 P15 
MSC (♀) Mean 93 88.67 83.67 83.33 
  ± S.E.M. 2.517 3.844 7.172 4.096 
MSC (♂) Mean 89.33 54.76 84.33 85.33 
  ± S.E.M. 4.372 5.219 1.453 5.783 
 
 
Table 4. Differentiation of AHPCs after Co-culture with MSCs 
  AHPC NCCC CCC 
TuJ1 21.46 23.11 19.74 
 ±  8.765 ±  4.473 ±  6.918 
RIP 59.15 29.45 54.61 
  ±  13.04 ±  8.102 ± 7.98 
BrdU 36.89 29.76 38.23 
  ± 10.22 ±  7.648 ± 10.94 
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Fig 1. Morphology of MSCs 
 
 
Fig 2. Characterization of MSCs 
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Fig 3. Differentiation of MSCs- Adipogenesis and osteogenesis 
 
 
 
 
 
 
 
 
 
 78 
 
Figure 4. Contact Co-culture (CCC) of AHPCs with MSCs. 
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(D) 
 
Figure 5. Sholl analysis for the quantification of neurite outgrowth of the AHPCs. 
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Figure 6. Oligodendrocyte differentiation of AHPCs following co-culture with MSCs.  
 
 
Supplementary materials (Data of ♀ BN-MSCs) 
 
 
Supplementary Fig 1. Characterization of MSCs  
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Supplementary Fig 2. Endogenous expression of neural marker  
 
 
Supplementary Fig 3. PI staining on MSCs 
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Supplementary Fig 4. Differentiation of MSCs- Adipogenesis and osteogenesis 
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Abstract  
The purpose of this study was to develop cellular vehicles to deliver neurotrophic 
factors as a part of neuroprotective strategies for rescuing neurodegenerative retina. In the 
U.S., millions of people suffer from ocular diseases, which eventually can lead to vision loss. 
Glaucoma, the second leading cause of blindness in the world, is a hereditary ocular disease 
which afflicts about 60 million individuals [1]. Currently, there are no remedies to cure 
glaucoma. As a potential strategy to rescue degenerating retinas, stem cells have been 
investigated extensively and the effects of morphological neuroprotection or functional 
recovery have been reported [2-5]. Mesenchymal stem cells (MSCs) are self-renewing, 
multipotent stromal cells and can be isolated from a variety of regions in the body. Bone 
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marrow-MSCs are relatively easily isolated and have been used in numerous studies as a 
potential candidate to develop therapeutic strategies for various diseases [6-22]. More 
importantly, bone marrow-MSCs are a potential candidate for autologous transplantation, 
which avoids immune responses in the host. In this study we infected mouse bone marrow-
derived MSCs with lentiviral vectors, which encode brain-derived neurotrophic factor 
(BDNF)/or glial cell-derived neurotrophic factor (GDNF) together with green fluorescent 
protein (GFP). Using fluorescence-activated cell sorting (FACS), enriched populations of the 
different GFP-expressing cells were collected. Our data showed MSCs infected with 
lentiviral vectors noticeably increased the expression of BDNF and/or GDNF protein in the 
cells. In addition, the amount of the secreted neurotrophic factors was highly increased and 
these were bioactive, as demonstrated by ELISA and an in vitro bioassay, respectively.  
These engineered MSCs were transplanted into mouse eyes of glaucoma models as 
potential neuroprotectors in vivo. The outcome is discussed in the next research chapters.  
 
Introduction  
Bone marrow-derived mesenchymal stem cells (MSCs) are a potential source for 
stem cell-based therapies, since they have several advantages, including 1) easy isolation and 
culture, 2) significant plasticity, 3) no ethical concerns, 4) capability to survive and migrate 
in vivo after transplantation [23, 24], 5) potential autologous transplant, and 6) availability of 
engineering to produce a cellular vehicle for long-term neurotrophic factor delivery. The 
axoplasmic flow of retinal ganglion cells is disturbed in the condition of ocular hypertension 
and, thus, retrograde transport of neurotrophic factors and the receptors are interrupted [25-
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28]. Therefore, many studies have been performed to deliver the interested genes or proteins 
to the target regions to prevent neuronal death from the deprivation of trophic factors. 
Injection of purified proteins, such as ciliary neurotrophic factor (CNTF) [29], Adeno-
associated viruses (AAVs) encoding trophic factors [30], or microspheres releasing GDNF 
[31, 32] into the eyes of animal models, have shown neuroprotective effects on the 
degenerating RGCs to some extent. However, these methods do not provide consistent and 
long-term support of trophic factors to the target region of interest.  
Taking into consideration the numerous advantages of MSCs, it is possible that 
delivery of neurotrophic factors via MSCs may be a useful strategy to overcome such 
limitations of short-term effects or an uncontrolled release of proteins in vivo. Utilizing 
MSCs, as a cellular vehicle to deliver neurotrophic factors, has been successful to rescue 
injured or degenerating retinal cells in vivo [4, 5].  
Engineering MSCs ex vivo is another powerful strategy for the delivery of the genes 
and gene products of interest. Viral vectors can be used as a potent tool for delivering genes 
to engineer MSCs. In this study, lentiviral vectors (LVs) were used to genetically engineer 
MSCs. Lentiviral vectors (LV) are a potent and efficient construct to deliver genes into non-
dividing and dividing cells. In addition, lentiviral constructs are a self-inactivating vector, 
possess the capability to integrate into the genome of host cells, and can result in sustained 
expression of the transgene [33-35]. Lentiviral vectors have been studied for use in gene 
therapy in vivo as well and have shown success on efficient transfer of genes and the 
protection of degenerating retinas [36-44].  
However, concerns with these vector applications exist, due to the low efficiency of 
viral infection to mature retinal neurons in vivo [45] and transient toxicity on the retinas [46] 
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when used directly into the eyes. Thus, we utilize lentiviral vectors to infect stem cells ex 
vivo for cell-based therapy. These constructs are a very powerful and desirable vehicle to 
deliver genes into the cells, as they are highly efficient for cell infection and can be 
manufactured on a large scale for use in therapeutic treatments [47].  
In this study we have employed lentiviral vectors to engineer bone marrow derived-
MSCs as cellular delivery vehicles for BDNF and GDNF. Our results demonstrate lentiviral 
constructs infect MSCs efficiently and induce significant increase of BDNF and GDNF 
expression in the MSCs. In addition, the levels of secreted BDNF and GDNF are 
significantly greater than control MSCs, and the secreted neurotrophic factors are bioactive.  
These engineered MSCs may have significance in therapeutic applications to serve as 
transplants to deliver neurotrophic factors for neurodegenerative diseases. Our strategy is to 
use engineered MSCs as a cellular vehicle of neurotrophic factor delivery for the 
glaucomatous eye. The MSCs are transplanted into glaucomatous eyes in animal models and 
can survive for a long-term period, releasing bioactive neurotrophic factors.   
 
     Materials and Methods 
Mouse mesenchymal stem cells (MSCs) 
Mouse MSCs isolated from the bone marrow of adult C57BL/6 mice were obtained 
from Tulane Center for Gene Therapy (New Orleans, LA) and maintained as an adherent cell 
line in Iscove's Modified Dulbecco's Medium (IMDM; 12440–046; Invitrogen, Carlsbad, 
CA) containing 10% hybridoma-qualified FBS (Cat #-SH30396.03, Hyclone, Logan, UT), 
10% equine serum (Cat #- SH3007403, Hyclone, Logan, UT), 2 mM L-glutamine, and 
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10,000 U/mL penicillin, 10,000 µg/mL streptomycin. When cultures reached 70–80% 
confluence, MSCs were gently detached from the flask using a 0.05% trypsin and 0.1% 
EDTA solution (Invitrogen) and were pelleted at 500 rpm for 5 minutes. MSCs were 
subsequently plated into T75 flasks at low confluence. Cultures were maintained by 
supplementing the flask with fresh medium every other day. 
 
Engineering MSCs Ex Vivo with lentiviral vectors 
MSCs were infected using lentiviral vectors to engineer them to secrete brain-
derived neurotrophic factor (BDNF; human cDNA) and glial cell-derived neurotrophic factor 
(GDNF; human cDNA), as previously reported [48]. Briefly, MSCs were plated in six-well 
plates at a density of 10,000 cells per well and were allowed to adhere for a day. After 
adhering to the plate, the growth medium in each well was replaced with IMDM, containing 
2% FBS and 12 µg/mL Sequa-brene (152667; Sigma-Aldrich, St. Louis, MO). Each 
lentiviral vector’s encoding BDNF (LV-BDNF; CMV-BDNF-IRES-GFP), GDNF (LV-
GDNF; CMV-GDNF-IRES-GFP), and green fluorescent protein (GFP, LV-GFP; CMV-GFP) 
were added separately to MSCs at a multiplicity of infection (MOI) of 1,000 for each vector. 
Media containing viral particles were removed after 8 hours of incubation and fresh growth 
medium was added. When confluence reached 70–80%, MSCs were transferred to a flask for 
subsequent maintenance. Subcultures were performed as described above. MSCs, that 
expressed strong green fluorescence, were collected by fluorescence-activated cell sorting 
(FACS). To sort MSCs by FACS, MSCs (BDNF- and GDNF-MSCs) were collected in 
separate 15 ml tubes. Each sample tube contained 3 to 5 million MSCs in 0.5 ml culture 
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media. Then, MSCs with strong green fluorescence were collected in separate catch tubes 
containing 1 ml FBS. Additionally, GDNF/BDNF-MSCs were generated by infecting 
GDNF-MSCs, which were previously sorted by flow cytometry, with the LV-BDNF vector 
at a MOI of 1,000. 
 
ELISA of BDNF and GDNF production 
Enzyme-linked immunosorbent assay (ELISA) was performed to quantify the 
amount of BDNF and GDNF released from GFP-MSCs, BDNF-MSCs, GDNF-MSCs, and 
GDNF/BDNF-MSCs. BDNF- and GDNF-assays (Emax Immunoassay System, G7611 and 
G7621, respectively; Promega Corporation, Madison, WI) were used to detect BDNF and 
GDNF, respectively, in media conditioned for 24 hours by each group of MSCs. Initially, 
250,000 cells were plated into a T25 flask and allowed to adhere for a day. Media were then 
replaced with fresh growth media, and cells were grown for an additional 24 hours. 
Conditioned media (CM) were collected, filtered using sterile 0.2 µm syringe filters, and 
frozen at -20°C for subsequent analysis. For BDNF assay, anti-BDNF monoclonal antibody 
in carbonate buffer was used to coat the wells of a 96-well plate overnight at 4°C. These 
wells were incubated with blocking and sample buffer for 1 hour at room temperature. 
Purified BDNF was used to generate the standard curve (0–500 pg/well). Samples from CM 
were prepared and incubated in wells on a shaker for 2 hours. Wells were subsequently 
washed. An anti-BDNF polyclonal antibody was added to the wells and plates were 
incubated again on a shaker for 2 hours. An anti-IgY horseradish peroxidase–conjugated 
antibody was incubated in the wells on a shaker for 1 hour at room temperature and 
 89 
subsequently washed. Chromagen substrate 100 µL (TMB-One solution; Promega) was 
added to each well and reacted for 10 minutes at room temperature. Reactions were stopped 
by adding 100 µL of 1 N HCl per well.  
For GDNF assay, an anti-GDNF monoclonal antibody in a carbonate buffer was 
utilized to coat the wells of a 96-well plate overnight at 4°C. Wells were incubated with a 
block and sample buffer for 1 hour at room temperature. Purified GDNF was used to 
generate the standard curves (0–1,000 pg/well). Samples from CM were prepared and 
incubated in wells on a shaker for 6 hours. Wells were subsequently washed. An anti-GDNF 
polyclonal antibody was added to the wells and plates were incubated overnight at 4°C. An 
anti-Chicken IgY, horseradish peroxidase–conjugated antibody was incubated in the wells on 
a shaker for 2 hours at room temperature and subsequently washed. Chromagen substrate 100 
µL (TMB-One solution; Promega) was added to each well and reacted for 10 minutes at 
room temperature. Reactions were stopped by adding 100 µL of 1 N HCl per well. All plates 
were read using a microplate reader at 450 nm. 
 
Bioactivity assay of neurotrophic factors 
Bioactivity for BDNF and GDNF released from the MSCs was examined using an in 
vitro assay. For this bioassay, PC12-TrkB cells (a generous gift from Dr. Chao, NYU) and 
PC12 cells (ATCC, Manassas, VA) were used to test for neurite outgrowth promoting 
activity [79, 80] of the MSC-derived BDNF and GDNF, respectively. Cells were plated onto 
a laminin (10 µg/ml)-coated surface of a 24-well culture plate and allowed to attach to the 
surface for a day. The next day, CMs were added into each well and cultures were 
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maintained in a mixed medium consisting of PC12-trkB cell/or PC12 cell growth media in a 
1:1 mixture with MSC-CM. The following conditions were tested: five different groups of 
CMs collected from 1) wild-type (Wt) MSCs, 2) GFP-MSCs, 3) BDNF-GFP-, 4) GDNF-
GFP-, 5) GDNF/BDNF-MSCs, and 6) fresh maintenance medium (MM), and 7) 50 ng/ml 
NGF (nerve growth factor), 8) 50 ng/ml recombinant human BDNF (rhBDNF, 450-02; 
PeproTech, Rocky Hill, NJ), or 9) 50 ng/ml recombinant human GDNF (rhGDNF, Cat #- 
450-10)-containing MSC media as positive controls. Cells were cultured up to 6 days for 
each condition. Phase contrast images were taken to perform a semi-quantitative analysis of 
neurite outgrowth. The level of neurite outgrowth was scored from 0 to 4, with 0 representing 
little neurite growth in terms of length and density, and 4 representing long, dense neurite 
outgrowth (Fig. 3).  
 
Immunocytochemistry 
For immunolabeling, MSCs were fixed in 4% paraformaldehyde in 0.1 M PO4 
buffer, pH 7.4. Fixed cells were incubated in blocking solution containing 5% normal donkey 
serum, 0.4% bovine serum albumin (BSA; Sigma), and 0.2% Triton X-100 (Fisher Scientific), 
followed by incubation with primary antibodies overnight at 4°C. Primary antibodies used 
were anti-BDNF (1:200, Santa Cruz Biotechnology, Dallas, TX), anti-GDNF (1:200, Santa 
Cruz Biotechnology, Dallas, TX). After rinsing in PBS, cells were incubated in the secondary 
antibodies conjugated to Cy3 diluted at 1:500 (Jackson ImmunoResearch, West Grove, PA). 
Cell nuclei were stained with 4’, 6-diamidino-2-phenylindole, dilactate (DAPI), diluted at 
1:1,000 in PBS and applied for 30 minutes. Preparations were rinsed and then mounted onto 
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microscope slides using an antifade mounting medium (Gel Mount; Biomeda Corp., Foster 
City, CA). Negative controls were performed in parallel by omission of the primary 
antibodies. No antibody labeling was observed in the controls.  
 
Quantitative analysis of neurotrophic factor expression on the MSCs 
To analyze the expression level of BDNF and GDNF on the MSCs, a pixel count was 
performed on the staining of BDNF and GDNF using ImageJ software. Images were taken 
with 630X magnification on a fluorescence microscope and more than 40 cells per MSC 
group were anayzed for pixel count. The threshold for the minimum pixel intensity value was 
set so the program would recognize a baseline where no background fluorescence was 
observed in the image. Then, the integrated intensity value was measured for BDNF and 
GDNF staining. Lastly, the intensity value was divided by unit area for each cell so that the 
values from different sized cells can be compared. 
 
 
Imaging and statistics 
Images of MSCs labeled with the antibodies were captured using an upright 
fluorescence microscope (Nikon Microphot FXA) equipped with a Retiga 2000R digital 
camera controlled by QCapture software (QImaging, Surrey, British Columbia, Canada). 
Figure plates were prepared using Photoshop CS2. Data were reported as means ± S.E.M. 
Statistical analysis was performed using GraphPad PRISM (ver. 3.0). All tests were two-
tailed tests and P values less than an alpha of 0.05 were considered significantly different.  
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Results 
Increased expression of neurotrophic factors in the MSCs  
We sought to generate different subpopulations of MSCs that release BDNF, GDNF, 
or both BDNF and GDNF together with GFP. Cultured MSCs were infected with three 
different LV-constructs at a MOI of 1,000 for each vector, and four types of LV-MSCs were 
engineered; GFP-, BDNF-, GDNF-, and GDNF/BDNF-MSCs. Infected cells, concurrently 
expressing green fluorescent protein, were visualized under a fluorescent microscope to 
assess the efficiency of the viral infection. Infection with GFP-LVs showed 100% efficiency 
and all the GFP-MSCs displayed a strong green fluorescence (Figure 1). Infection 
efficiencies for the BDNF- and GDNF-MSCs was between approximately 50 and 80%, based 
on GFP-expression. To enrich for the infected cells (based on GFP-expression), these MSC 
populations were subjected to FACS analysis. A population of MSCs expressing both GDNF 
and BDNF were produced by infecting the GDNF-MSCs (previously enriched by FACS) 
with the BDNF lentiviral vector. After FACS, all MSC populations were expanded further.  
The expression of the neurotrophic factors in the MSCs was examined by 
immunocytochemistry, using specific antibodies directed against BDNF and GDNF (Figure 
1). A stronger immunoreactivity (IR) of BDNF was observed on the BDNF- and 
GDNF/BDNF-MSCs, compared to that for GDNF- and GFP-MSCs. Robust BDNF 
expression was observed on the cell body, including the nucleus. No specific IR was found 
on the negative control stain, done by omitting the primary antibodies (Figure 1A).  
Immunoreactivity for GDNF expression was greatest on the GDNF- and 
GDNF/BDNF-MSCs, compared to that for GFP- and BDNF-MSCs. A notably stronger IR 
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was observed on the MSCs infected with GDNF-LVs. The cellular location of GDNF was 
present in the cell body, but not in the nucleus (Figure 1B).  
The levels of neurotrophic factor expression on the MSCs were quantified by 
analyzing the number of pixels per unit area (Figure 2). In accordance with Figure 1, both 
BDNF- and GDNF/BDNF-MSCs showed prominently increased expression of BDNF than 
for GDNF-MSCs. Also, both GDNF- and GDNF/BDNF-MSCs showed an elevated level of 
GDNF expression, compared to BDNF- and GFP-MSCs. Moreover, GDNF/BDNF-MSCs 
expressed increased levels of GDNF as well as BDNF. Additional experiments are required 
to conclude statistical significance of the values.  
 
Enhanced secretion of neurotrophic factors from the MSCs 
To examined whether engineered MSCs were capable of secreting BDNF and GDNF, 
ELISA analyses were conducted on the media conditioned by the engineered MSCs (Table 
1). No detectable BDNF and GDNF were found from the conditioned media (CM) from the 
control, GFP-MSCs. However, BDNF-MSCs released an increased amount of BDNF (5.9 
ng/10
6
 cells/24 hrs) while GDNF was not detected. An elevated amount of GDNF (34.1 
ng/10
6
 cells/24 hrs) was detected in the GDNF-MSC CM, with no detectable BDNF. 
GDNF/BDNF-MSCs secreted comparable amounts of BDNF (3.2 ng/10
6
 cells/24 hrs) and 
GDNF (33.8 ng/10
6
 cells/24 hrs) to that of BDNF- and GDNF-MSCs, respectively. Together 
these results demonstrate that the lentiviral transduced MSCs were capable of producing and 
secreting the respective neurotrophic factor.  
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Bioactivity of neurotrophic factors released from the MSCs 
An in vitro assay was implemented to investigate the bioactivity of the neurotrophic 
factors released from the engineered MSCs. PC12 cell lines were cultured in media 
conditioned by the different MSC populations to determine the effect of MSC secreted 
neurotrophic factors on neurite outgrowth. Bioassays were performed on a laminin (10 
µg/ml)-coated surface of a 24-well culture plate. 500 µl of media, 1:1 mixture of PC12 cell 
culture media with MSC-CM, were added into each test wells. A total of nine different 
conditions were tested: MSC CMs collected from 1) Wt-, 2) GFP-, 3) BDNF-, 4) GDNF-, 
and 5) GDNF/BDNF-MSCs, and also controls, including 6) fresh maintenance medium 
(MM), 7) 50 ng/ml NGF, 8) 50 ng/ml recombinant human BDNF (rhBDNF), and 9) 50 ng/ml 
recombinant human GDNF (rhGDNF). Wt-MSCs were used as a cell control and they were 
not infected by lentiviral vectors. By culturing PC12-TrkB cells in MSC CMs (Figure 4A), 
the bioactivity for BDNF was assessed. At 4 days in vitro (DIV), the neurite outgrowth of 
PC12-TrkB cells had significantly increased in BDNF- and GDNF/BDNF-MSC CMs, 
compared to those for the Wt-, GFP-, and GDNF-MSC CMs and control MM conditions. 
The growth of neurites in BDNF- and GDNF/BDNF-MSC CMs was comparable to that for 
the positive control—50 ng/ml rhBDNF.  
Bioactive GDNF was revealed from the culture of PC12 cells in MSC CMs (Figure 
4B). At 6 DIV of culture, a significantly increased level of neurite outgrowth of PC12 cells 
was measured in GDNF- and GDNF/BDNF-MSC CMs, compared to that in the Wt-, GFP-, 
and BDNF-MSC CMs and MM. The neurite outgrowth enhanced in the GDNF- and 
GDNF/BDNF-MSC CMs was comparable to that for the positive control—rhGDNF 50 
ng/ml. Statistical significance for the differences is shown on Table 2. These results 
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demonstrate that both BDNF and GDNF released from genetically engineered MSCs are 
bioactive in vitro. Also, GDNF/BDNF-MSCs secrete comparable amounts of GDNF and 
BDNF to enhance neurite outgrowth, compared to that of GDNF- and BDNF-MSCs, 
respectively.    
Additionally, we have confirmed stable expression and release of neurotrophic factors 
from engineered MSCs, which have been subcultured for an extended period of time. Also, 
repetitive freezing-thaw procedures have not affected the capability of MSCs to release 
neurotrophic factors.  
 
Discussion 
We have demonstrated the lentiviral infection on the MSCs is a competent method to 
deliver genes of interest. Genetic engineering using lentiviruses is a very powerful and 
efficient strategy to deliver genes into cells, as it allows a stable and long-term expression of 
the genes [33, 38, 49]. Lentiviral vectors are capable of delivering genes into non-dividing 
cells [34, 50-52] as well as stem cells [53-55]. We used bicistronic lentiviruses, which 
allowed the MSCs to concurrently express BDNF/or GDNF with GFP. Thus, the engineered 
MSCs can be visualized by expression of green fluorescent protein and easily detectable in 
vivo after transplant.  
Following the successful delivery of genes, we demonstrate the expression of the 
neurotrophic factor proteins are elevated in the MSCs. Immunostaining revealed that BDNF-
MSCs expressed an increased level of BDNF protein, unlike GFP- and GDNF-MSCs. 
GDNF-MSCs showed elevated expression of GDNF protein, unlike GFP- and BDNF-MSCs. 
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Double-infection with GDNF- and BDNF-LVs also resulted in an over-expression of both 
GDNF and BDNF proteins in the MSCs. Release of GDNF and BDNF from the MSCs has a 
significance as that may have implications in therapeutic strategy to treat neurodegenerative 
diseases, including glaucoma. Previous in vitro studies have demonstrated neuroprotective 
effects of BDNF and GDNF on neuronal cells, including RGCs [56-61]. These effects have 
also been shown in animal models of retinal disease or injury [5, 30, 62-65] as well as brain 
injury [66].  
The co-expression of both GDNF and BDNF in the MSCs is a novel aspect to our strategy. 
Synergistic or combined effects of BDNF and GDNF have been reported for neuroprotection 
and differentiation for neurons [67-70]. Previous studies have suggested that BDNF and 
GDNF act in a distinct mode when they are combined for treatment of motorneurons as they 
show synergistic or combined effects on neuronal differentiation [67] and neuroprotection 
[68]. In addition, co-administration of BDNF and GDNF exerts additive effects on RGC 
survival in a rat model of optic nerve transaction [71].  
BDNF has been shown to activate MAPKinase, Ras/Raf/MEK/ERK, and 
PI3K/Akt/mTOR pathways, which promote cell survival and growth [72-74]. BDNF also 
binds to p75NT receptor and results in apoptosis via the activity of Jun N-terminal kinase 
(JNK) [72]. GDNF has been known to activate not only PI3K and MAPkinase pathways, but 
also PLC-Ɣ and Src-family kinase signaling [75]. A study also reported a temporal 
discrepancy on the phosphorylation of MAPKinase by GDNF and BDNF. GDNF induces a 
transient phosphorylation, while BDNF results in a long lasting MAPK phosphorylation [74] 
Thus, we speculate BDNF and GDNF work independently to activate neuronal survival 
pathways and enhance RGC survival.  
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In addition to the cellular expression for BDNF and GDNF proteins, we demonstrate 
the secretion of the neurotrophic factors from the engineered MSCs increased. Slightly 
higher levels of BDNF-IR on the GFP-MSCs were found, when comparing with ELISA, 
which had no detectable BDNF (Table 1). This possibly indicates either BDNF protein was 
produced in the cells, but not secreted, or crossover interference of a strong green 
fluorescence occurs in the cells. It has been shown that MSCs endogenously express different 
types of trophic factors, including BDNF, GDNF, NGF, CNTF, neurotrophic -3 (NT-3) [76, 
77] as well as immunosuppressive, angiogenic, and proliferation-stimulating factors [78]. A 
previous study demonstrated that MSCs are capable of secreting BDNF, along with a 
significant increase of BDNF secretion from the MSCs following BDNF gene delivery [5]. It 
is possible that the low sensitivity of ELISA kits we utilized may result in a lack of 
detectable BDNF and GDNF from CM for our GFP-MSCs. Additional studies, such as 
Western blotting, may also be useful to investigate neurotrophic factor expression in the 
MSCs, as well as the amount of neurotrophic factor secretion from the MSCs.  
We demonstrated the engineered MSCs possess the capability of hyper-secretion of 
BDNF and GDNF, which are bioactive. These results suggest MSCs are a potential delivery 
vehicle, which provides neuroprotection to degenerating or damaged cells by secreting 
neurotrophic factors. Also, MSCs are a robust population, grow fast, and avoid ethical issues 
related to human embryonic and fetal stem cell isolation. In addition, MSCs have the potency 
for use in clinical therapy, since they are a useful resource for autologous transplant and can 
be easily isolated from the body. Also, they have immunomodulatory functions.  
I discuss, in the next chapters, in vivo investigations of this cellular vehicle system to 
study the effects of BDNF and GDNF delivery in the experimental glaucomatous models.  
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Figure Legends  
Table 1. In vitro quantification of BDNF and GDNF released from engineered MSCs. ELISA 
was performed, using conditioned media (CM) collected from each group of MSCs. No 
BDNF and GDNF were detectable from the control GFP-MSCs, while BDNF-, GDNF-, and 
GDNF/BDNF-MSCs secreted elevated amounts of BDNF and/or GDNF. (Abbreviation; 
N.D.: not detectable) 
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Table 2. Statistical analysis of bioassays. One-way ANOVA with Tukey's multiple 
comparisons test was used. P＜0.05 was considered significant. **** = 0.0001. 
 
Figure 1. In vitro expression of BDNF and GDNF on the MSCs after lentiviral infection. To 
engineer MSCs to over-express BDNF and/or GDNF, wild-type MSCs were infected with 
lentiviral vectors (LV): GFP-, BDNF/GFP-, or GDNF/GFP-LVs. Infected cells concurrently 
expressed green fluorescent protein, which can be visualized under a fluorescent microscope. 
Subsequently, GDNF-MSCs were infected with BDNF-LVs to generate GDNF/BDNF-
MSCs. (A) BDNF-MSCs showed stronger immunoreactivity (IR) against BDNF than for 
GFP- and GDNF-MSCs, and (B) GDNF-MSCs showed a brighter immunoreactivity than for 
GFP- and BDNF-MSCs. No specific IR was found on the negative control stain, done  by 
omitting the primary antibodies.  Scale bars are 50 microns, and all images were taken with 
the same magnification. 
 
Figure 2. Quantification of BDNF and GDNF expression on the MSCs in vitro. 
MSCs stained against BDNF or GDNF proteins were quantified by measuring the number of 
pixels per unit area (2000 pixels) using ImageJ. BDNF- and GDNF-MSCs showed a notably 
increased expression of BDNF and GDNF, respectively. Also, both BDNF and GDNF were 
highly increased on GDNF/BDNF-MSCs. Error bars are standard deviation. N=1; Number of 
cells analyzed: > 40 cells per MSC group. 
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Figure 3. Representative images of bioassay. A semi-quantitative analysis was performed to 
assess neurite outgrowth from PC12 cells.  
(A) BDNF bioassay. PC12-TrkB cells were cultured in MSC CMs to test the bioactivity of 
BDNF released from MSCs. At 4 DIV, the neurite outgrowth was significantly increased in 
both BDNF- and GDNF/BDNF-MSC CMs, compared to those for the Wt- and GFP-MSC 
CMs and control MM conditions. The growth of neurites in the BDNF- and GDNF/BDNF-
MSC CMs was comparable to those for the positive controls—50 ng/ml rhBDNF and 50 
ng/ml NGF.  
(B) GDNF Bioassay. Bioactive GDNF was tested using PC12 cells by culturing in MSC 
CMs. At 6 DIV of culture, a significantly increased level of neurite outgrowth was observed 
in both GDNF- and GDNF/BDNF-MSC CMs, compared to those in the Wt- and GFP-MSC 
CMs, and MM. The growth of neurites in the GDNF- and GDNF/BDNF-MSC CMs was 
comparable to those for the positive controls—NGF 50 ng/ml and rhGDNF 50 ng/ml. Scale 
bars = 200 µm. 
Figure 4. In vitro assessment of bioactivity of BDNF and GDNF. The level of neurite 
outgrowth was scored from 0 to 4, with 0 representing no or little neurite growth in terms of 
length and density and 4 representing long, dense neurite outgrowth.  
(A) Bioactivity of BDNF released from BDNF- and GDNF/BDNF-MSCs was tested using 
PC12-TrkB cells. At 4 DIV culture, significantly higher levels of neurite outgrowth were 
measured from both BDNF- and BDNF/GDNF MSC-CMs, compared to those for the control 
Wt- and GFP-MSC CMs and MM groups.  
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(B) Bioactivity of GDNF released from GDNF- and GDNF/BDNF-MSCs was tested using 
PC12 cells. At 6 DIV, significantly increased level of neurite outgrowth of PC12 cells was 
shown in both GDNF- and GDNF/BDNF-MSC CMs, compared to those for the control 
groups—Wt- and GFP-MSC CMs and MM.  
NGF was used as one of the positive controls for neurite outgrowth of PC12 cell lines. Error 
bars are standard error. (N = 3) 
 
 
Tables and Figures 
Table 1. In vitro quantification of BDNF and GDNF released from engineered MSCs. 
MSC Groups  BDNF GDNF 
GFP MSC N.D. N.D. 
BDNF MSC 0.59 N.D. 
GDNF MSC N.D. 3.41 
GDNF/BDNF MSC 0.32 3.38 
                                      (ng/100,000 cells/24 hrs)   
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Table 2. Statistical analysis of bioassays. 
GDNF bioassay Significance BDNF bioassay Significance 
MM vs. GDNF-MSC *** MM vs. BDNF-MSC **** 
MM vs. GDNF/BDNF-MSC * MM vs. GDNF/BDNF-MSC **** 
MM vs. NGF **** MM vs. NGF **** 
MM vs. rhGDNF ** MM vs. rhBDNF **** 
Wt-MSC vs. GDNF-MSC *** Wt-MSC vs. BDNF-MSC **** 
Wt-MSC vs. GDNF/BDNF-
MSC * 
Wt-MSC vs. GDNF/BDNF-
MSC **** 
Wt-MSC vs. NGF **** Wt-MSC vs. NGF **** 
Wt-MSC vs. rhGDNF ** Wt- MSC vs. rhBDNF **** 
GFP-MSC vs. GDNF-MSC *** GFP-MSC vs. BDNF-MSC **** 
GFP-MSC vs. 
GDNF/BDNF-MSC ** 
GFP-MSC vs. GDNF/BDNF-
MSC **** 
GFP-MSC vs. NGF **** GFP-MSC vs. NGF **** 
GFP-MSC vs. rhGDNF ** GFP-MSC vs. rhBDNF **** 
BDNF-MSC vs. GDNF-
MSC *** BDNF- MSC vs. GDNF-MSC **** 
BDNF-MSC vs. 
GDNF/BDNF-MSC ** BDNF-MSC vs. NGF * 
BDNF-MSC vs. NGF **** BDNF-MSC vs. rhGDNF **** 
BDNF-MSC vs. rhGDNF ** 
GDNF-MSC vs. 
GDNF/BDNF-MSC **** 
GDNF-MSC vs. rhBDNF *** GDNF-MSC vs. NGF **** 
GDNF/BDNF-MSC vs. NGF * GDNF-MSC vs. rhBDNF **** 
GDNF/BDNF-MSC vs. 
rhBDNF ** GDNF/BDNF-MSC vs. NGF * 
NGF vs. rhBDNF **** 
GDNF/BDNF-MSC vs. 
rhGDNF **** 
rhBDNF vs. rhGDNF ** NGF vs. rhBDNF * 
  NGF vs. rhGDNF **** 
    rhBDNF vs. rhGDNF **** 
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(A)  
Figure 1. (Continued) 
 
 
 
 
 
 
 
 
(B) 
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Figure 1. In vitro expression of BDNF and GDNF on the MSCs after lentiviral infection.  
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Figure 2. Quantification of BDNF and GDNF expression on the MSCs in vitro. 
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   (A) 
 
Figure 3. (Continued) 
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(B) 
 
Figure 3. Representative images of bioassays. 
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Figure 4. In vitro assessment of bioactivity of BDNF and GDNF. 
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Abstract  
The purpose of this study was to develop neuroprotective strategies to rescue 
neurodegenerative retinas by stem cell-based therapy. Glaucoma, the second leading cause of 
blindness in the world, is a hereditary ocular disease, affecting about 60 million people 
throughout the world [1]. One significant factor that contributes to glaucoma is elevated 
intraocular pressure (IOP). Such hypertension causes the death of retinal ganglion cells 
(RGCs) and eventually leads to vision loss. However, there are no remedies to cure 
glaucoma, yet. As a potential solution to rescue degenerating retinas, stem cells have been 
investigated extensively and the effects of morphological neuroprotection or functional 
recovery have been reported [2-5]. Our previous study showed mesenchymal stem cells 
(MSCs) releasing brain-derived neurotrophic factor (BDNF) played a significant role to 
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rescue degenerating retinas, following ocular transplant in a chronic rat model of optic 
neuropathy [5]. In the present study we have investigated the potential effects on 
morphological and functional neuroprotection, using a chronic model of hereditary glaucoma, 
DBA/2J mice, by performing ocular injection of bone marrow-derived MSCs. Following an 
intraocular transplant, the engineered MSCs survived up to four months post transplant (PT) 
in adult host retinas without immunosuppression. Our histological examinations showed no 
cell proliferation in the host retina during all time points examined. In addition, we observed 
a potential role of MSCs on the alleviation of glial activation after MSC transplantation into 
the host retina. There was no noticeable decrease on the numbers of NeuN- and choline 
acetyltransferase (ChAT)-IR cells between 12 and 16 weeks post transplant (PT). Also, no 
significant difference was found on the proportions of both NeuN- and ChAT-IR cells 
between OS and OD in all groups. Howerver, there was a trend towards protecting NeuN-IR 
cells in the ganglion cell layer (GCL) by glial cell-derived neurotrophic factor (GDNF)- and 
GDNF/BDNF-MSCs. In addition, analysis of retinal architecture, assessed by retinal 
thickness, indicates potential neuroprotection on the inner retina mostly by GDNF/BDNF-
MSCs.  
Taken together, trends in the data suggest transplantation of MSCs, which secrete 
both BDNF and GDNF, is beneficial to the preservation of the host inner retina as well as 
retinal ganglion cells. This study provides an experimental strategy towards clinical 
applications in terms of using MSCs as a potential autograft, and long-term neuroprotection 
via neurotrophic factor delivery for retinodegenerative diseases. 
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Introduction 
Today, millions of people in the U.S. suffer from ocular diseases, which eventually 
can lead to vision loss. Glaucoma, the second leading cause of blindness in the U.S., is a 
hereditary ocular disease, affecting about four million Americans. Elevated IOP is one of the 
most significant risk factors contributing to glaucoma and RGC death is a major problem 
causing irreversible vision loss [6, 7]. Neurotrophic factors have been investigated and used 
in developing strategies to rescue injured/or degenerative retinas, since It has been reported 
that ocular hypertension contributes to the deprivation of neurotrophic factors by blocking 
retrograde transport [8, 9]. BDNF stimulated regrowth of RGC axons [10] and increased the 
survival of RGCs [11] in vivo. GDNF also has been shown to have the ability to promote 
RGC survival in degenerating retinas [12, 13].  
Engineering MSCs as cellular vehicles for neurotrophic factor delivery is a rational 
strategy towards overcoming challenging issues, such as sustained long-term secretion of 
bioactive NTs and repetitive injections into the eye. MSCs have shown neuroprotective 
effects on the survival of RGCs and/or their axons following intravitreal transplantation into 
the eyes with experimental glaucoma [3-5]. Previous studies have shown bone marrow-
derived MSCs injected into the vitreous cavity exerted neuroprotective effects on the RGC 
axons in a rat glaucoma model [4]. In addition, MSCs engineered to express BDNF rescued 
degenerating retinas structurally, as well as functionally [5]. So far, no study has shown 
significant neuroprotective effects, both structurally and functionally, on glaucomatous 
models for a long-term period, greater than 2 months post transplant. 
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DBA/2J mice are a hereditary, spontaneous glaucoma model and a very good model 
organism to study experimental glaucoma, because these mice are well-investigated and has 
characteristics of human glaucoma, including age-related progression of IOP elevation, RGC 
death, and excavation of the optic nerve head [14]. DBA/2J mice have shown a linear 
increase of IOP from 2 to 10 months of age, and the IOP is correlated with the preservation 
of the optic nerve, as well as corneal thickness [15]. Furthermore, it has been shown that 
around 13 months of age the number of RGCs and their axons, examined by retrograde 
tracers, decreased significantly. However, the number of NeuN-immunoreactive (IR) RGCs 
was not significantly reduced until 18 months of age [16]. Studies conducted with DBA/2J 
mice have demonstrated that the glial lamina, which corresponds to the lamina cribrosa in 
humans, and proximal to the laminar region are the first areas of axon degeneration in the 
optic nerve [17, 18]. 
It has been suggested that functional deficits in RGCs precede structural 
abnormalities and cell death [16, 19]. Pattern electroretinogram (PERG) provides a 
noninvasive electrophysiological assessment of visual function. Usefulness of PERG has 
been demonstrated as a tool to monitor the dysfunction of RGCs in DBA/2J mice [20]. It was 
also reported that DBA/2J mice showed a progressive decrease of PERG amplitude, starting 
after 3 months of age and diminished to noise level by 11 months of age [21].  
Many glaucomatous characteristics of morphological changes in the eyes of DBA/2J 
mice have been reported. Correlation between corneal thickness with IOP was revealed in 
DBA/2J mice. Increased corneal thickness, regardless of age, was observed with increased 
IOP. Moreover, decrease in axonal density was correlated with increased corneal thickness. 
The results indicated that corneal thickness is a good predictor of optic nerve degeneration 
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[15]. In addition, the timecourse of RGC changes in DBA/2 mice has also been examined. 
The deficits in axonal transport, found after 6 months age, precedes axonal loss and cell loss, 
observed at about 13- and 18-month old mice, respectively [16].  Furthermore, along with the 
degeneration of RGCs, glial changes in the retina and optic nerve are also crucial factors 
involved in the progression of glaucoma. Increased reactivity on the retinal astrocytes and 
Müller cells, and increased number of microglia were observed in aging DBA/2J mice after 
3- to 4-months of age [22, 23]. In addition, in the optic nerves of aged DBA/2J mice, there 
was an opposite correlation between astrocyte activation and axon labeling with antibodies 
directed against phosphorylated neurofilament. This astrocyte reactivity was observed in the 
early degeneration process and was followed by a later loss of oligodendrocytes [24]. The 
loss of oligodendrocytes occurred coincidently with axonal loss. Also, a proliferation of 
oligodendrocyte precursor cells was observed [24]. Microglial activation was found in 
severely degenerated optic nerves, and phagocytic activity of microglia was activated after 
axonal degeneration [24].     
  Thus, we will examine morphological changes of the DBA/2J retinas following 
MSC transplantation, mainly focusing on microglial and Müller glial changes, as well as 
RGC changes. These can be important indicators to monitor glaucomatous degeneration. The 
aim of the studies described in this paper are to investigate the long-term effects of BDNF- 
and GDNF-secreting mouse MSCs in a mouse model of experimental glaucoma, seeking 
structural and functional protection on degenerating retinas. We have employed both 
functional and morphological studies to evaluate our strategy for neuroprotection. We show 
that MSCs can survive up to 4 months PT in vivo, following intraocular transplantation. The 
recipient eyes showed reduced glial activation and a pattern of increased thickness of retinal 
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layers compared with the control, non-transplanted fellow eyes. More importantly, our results 
suggest transplanted MSCs may play an important role in the neuroprotection of RGCs in the 
host eyes.  
Overall, this study provides the first evidence of long-term survival of engineered 
MSCs in adult retina of DBA/2J mice. In addition, our results suggest bone marrow-derived 
MSCs can function as a potent cellular vehicle to deliver neurotrophic factors into the 
glaucomatous eyes and preserve the host retina.  
 
Materials and Methods   
Animals 
Female DBA/2J mice, obtained from the Jackson Laboratory, at 7-8 months of age 
were used for MSC transplantation. The animals were kept in a constant environment 
(temperature: 22°C; humidity: 20 %; 14/10-hour light-dark cycle) with food and water 
provided ad libitum. The mice were allowed to rest for 7 days after arrival from the supplier 
to let them recover from transportation and adapt to the new environment before performing 
intraocular injection. All animal procedures for this study adhered to the provisions of the 
Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of 
Animals in Ophthalmic and Vision Research, and had the approval of the Iowa State 
University Institutional Animal Care and Use Committee, and were performed in accordance 
with committee guidelines. 
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Mouse mesenchymal stem cells (MSCs) 
Mouse MSCs isolated from the bone marrow of adult C57BL/6 mice were obtained 
from Tulane Center for Gene Therapy (New Orleans, LA) and maintained as an adherent cell 
line in Iscove's Modified Dulbecco's Medium (IMDM; 12440–046; Invitrogen, Carlsbad, 
CA) containing 10% hybridoma-qualified FBS (Cat #-SH30396.03, Hyclone, Logan, UT), 
10% equine serum (Cat #- SH3007403, Hyclone, Logan, UT), 2 mM L-glutamine, and 
10,000 U/mL penicillin, 10,000 µg/mL streptomycin and maintained at 37 ℃ and CO2 level.. 
When cultures reached 70–80% confluence, MSCs were gently detached from the flask using 
a 0.05% trypsin and 0.1% EDTA solution (Invitrogen) and were pelleted at 500 rpm for 5 
minutes. MSCs were subsequently plated into 75 cm
2
 flasks at low confluence. Cultures were 
maintained by supplementing the flask with fresh medium every other day. 
 
Engineering MSCs Ex Vivo with lentiviral vectors 
MSCs were infected using lentiviral vectors to engineer them to secrete brain-
derived neurotrophic factor (BDNF; human cDNA) and glial cell-derived neurotrophic factor 
(GDNF; human cDNA), as previously reported [25]. Briefly, MSCs were plated in six-well 
plates at a density of 10,000 cells per well and were allowed to adhere for a day. After 
adhering to the plate, the growth medium in each well was replaced with IMDM, containing 
2% FBS and 12 µg/mL Sequa-brene (152667; Sigma-Aldrich, St. Louis, MO). Separate 
lentiviral vector’s encoding BDNF (LV-BDNF; CMV-BDNF-IRESGFP), GDNF (LV-
GDNF; CMV-GDNF-IRESGFP), and green fluorescence protein (GFP, LV-GFP; CMV-
GFP) were added separately to MSCs at a multiplicity of infection (MOI) of 1,000 for each 
 122 
vector. Media containing viral particles were removed after 8 hours of incubation and fresh 
growth medium was added. When confluence reached 70–80%, MSCs were transferred to a 
flask for subsequent maintenance. Subcultures were performed as described above. MSCs, 
that expressed strong green fluorescence, were collected by fluorescence-activated cell 
sorting (FACS) using an equipment FACSAria III (BD Biosciences, San Jose, CA) 
controlled by BD FACSDiva software (version 6.1.3). To sort MSCs by FACS, each BDNF- 
and GDNF-MSCs were collected in separate 15 ml tubes. Each sample tubes contained 3 to 5 
million MSCs in 0.5 ml culture media. Then, MSCs with strong green fluorescence were 
collected in separate catch tubes containing 1 ml FBS. Additionally, GDNF/BDNF-MSCs 
were generated by infecting GDNF-MSCs, which were previously FACS sorted with the LV-
BDNF constructs at a MOI of 1,000.  
 
Cell transplantation 
To perform intraocular injections, MSCs were collected by gently detaching the cells 
with a 0.05% trypsin and 0.1% EDTA solution (Invitrogen, Carlsbad, CA), and pelleted at 
500 rpm for 5 minutes. Supernatant media were removed and the pellet was resuspended 
with Earle's Balanced Salt Solution (EBSS, Invitrogen, Carlsbad, CA) at a concentration of 
50,000 cells per µl. A beveled glass microelectrode attached to a Hamilton syringe via 
polyvinyl chloride tubing was used to inject 2 µl of MSC cell suspension intravitreally. Only 
the left eye served as an experimental group and the right eye served as a fellow, control eye. 
Five different groups of injections were included; (1) BDNF-GFP-MSCs, (2) GDNF-GFP-
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MSCs, (3) GDNF/BDNF-MSCs, (4) GFP-MSCs as a cell control, and (5) Earle's Balanced 
Salt Solution (EBSS) as an injection control.    
 
Measurement of intraocular pressure (IOP) 
A TonoLab rebound tonometer (Colonial Medical Supply, Franconia, NH) was used 
to monitor the IOP in both experimental and control eyes, following the procedures described 
in the manufacturer’s manual. Briefly, mice were anesthetized with 1 L/min O2 and 3.5% 
isoflurane for initial induction, and maintained at 1.5% isoflurane through IOP measurement. 
Measurement was performed 3-4 minutes after anesthesia induction. The TonoLab acquires 
six rebounds of the probe from the corneal surface and calculates a mean of the middle four 
measurements. Body temperature was maintained on a heating pad during measurements. 
 
Pattern electroretinogram (PERG) 
To evaluate functional RGCs, PERG was used to measure the retinal potential. The 
mice were anesthetized with 1 L/min O2 and 3.5% isoflurane for initial induction, and 
maintained at 1.5% isoflurane through PERG recording. Before PERG recording was started, 
the mice were dark-adapted for 10 min. After induction of anesthesia, the mice were placed 
on a stainless steel recording table equipped with a hot water-based warming platform to 
maintain body temperature. One percent tropicamide was applied to the cornea. Reference 
and ground electrodes were placed subcutaneously on the forehead and tail of the animal, 
respectively. A gold recording electrode (Roland Consult, Brandenburg, Germany) was 
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gently placed on the cornea and a drop of methylcellulose was used to maintain contact 
between the electrode and cornea. The mouse’s head was positioned 15 cm from the stimulus 
monitor. Stimuli were evoked using alternating, reversing, black and white vertical stimuli 
delivered on a CRT monitor with a ERG system (Reti-Port System; Roland Consult). Stimuli 
of 0.02 cycles per degree (cpd), 1 Hz frequency, 200 averaged signals with cut off filter 
frequencies of 1-30 Hz were delivered to maximize PERG amplitude. For analysis, 
amplitudes from peak to trough of the waveforms were evaluated.  
 
Tissue preparation and immunohistochemistry 
The mice were deeply anesthetized with isoflurane and quickly euthanized by 
cervical dislocation. The eyes and optic nerves were fixed with 4% paraformaldehyde (pH 
7.4). The optic nerves were dissected from the eye globes and embedded in paraffin for 
subsequent procedures. The eye globes were cryoprotected in 30% sucrose and embedded in 
the Optimum Cutting Temperature (OCT) compound (Tissue-Tek, Torrance, CA). Frozen 
retinal sections were prepared in 16 µm thickness and examined for immunohistochemistry 
analysis. A panel of primary antibodies was used for histological examinations. The tissue 
sections were incubated in a blocking solution containing 5% normal donkey serum and 
0.2% Triton X-100 (Fisher Scientific), followed by incubation with primary antibodies 
overnight at 4°C. The primary antibodies used were anti-GFAP (1:500, Fisher Scientific, 
Pittsburgh, PA), anti-Iba1 (1:400, Wako, Richmond, VA), anti-BDNF (1:200, Santa Cruz 
Biotechnology, Dallas, TX), anti-GDNF (1:200, Santa Cruz Biotechnology, Dallas, TX), 
anti-phospho-histone H3 (pH3) (1:1,000, Abcam, Cambridge, MA), anti-caspase 3 (1:200, 
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Millipore, Billerica, Massachusetts), anti-GFP (1:400, Millipore, Billerica, Massachusetts), 
anti-NF68 (1:200, Abcam, Cambridge, MA), anti-neurofilament (NF) 200 (1:200, Sigma-
Aldrich, St. Louis, MO), and GFAP-Cy3 conjugated (1:1,000, Sigma-Aldrich, St. Louis, 
MO). After rinsing in phosphate buffered saline (PBS), the sections were incubated with the 
secondary antibodies conjugated to Cy3 (1:500, Jackson ImmunoResearch, West Grove, PA), 
FITC (1:500, Jackson ImmunoResearch, West Grove, PA), or Cy5 (1:500, Jackson 
ImmunoResearch, West Grove, PA). Cell nuclei were stained with 4’, 6-diamidino-2-
phenylindole, dilactate (DAPI), diluted at 1:2,000 in PBS, and applied for 30 minutes. 
Preparations were rinsed and then mounted onto microscope slides using an anti-fade 
mounting medium (Gel Mount; Biomeda Corp., Foster City, CA). Negative controls were 
performed in parallel by omission of the primary antibodies. No antibody labeling was 
observed in the controls.  
 
Quantification of retinal layer thickness 
To evaluate the effect of the transplanted MSCs on the preservation of the host 
retinal architecture, the thickness of retinal layers was measured. Three medial cross-sections 
for each eye were analyzed. Retinal sections were stained with a cocktail of Phalloidin-
conjugated with Alexa Fluor 488 (1:1,500, Invitrogen, Carlsbad, CA) and DAPI (1:2,000). 
The thickness measurements for each retinal layer were compiled for both peripheral and a 
central retinal image taken of each cross-section. Using ImageJ software, standardized grid 
coordinates were generated within each image. Then, three lines, aligning perpendicular to 
the retinal layers and distributed equidistant from each other, were analyzed within each 
image. The thickness of the outer and inner nuclear layers was measured based on DAPI 
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staining. Phalloidin staining was used to measure the thickness of the outer and inner 
plexiform layers, and the ganglion cell layer together with the nerve fiber layer. Analysis was 
performed in a masked manner. 
 
Retinal imaging and statistics 
The retinal images were photographed, using an upright fluorescence microscope 
(Nikon Microphot FXA) equipped with a Retiga 2000R digital camera controlled by 
QCapture software (QImaging, Surrey, British Columbia, Canada). Figure plates were 
prepared using Photoshop CS2. For quantitative analyses, data were reported as means ± 
S.E.M. Statistical analysis was performed by using Student’s t-test, paired t-test, and one-
way ANOVA (GraphPad, San Diego, CA). P＜0.05 was considered significant. 
 
Results 
IOP measurement after MSC transplantation 
Elevated IOP is a significant risk factor for glaucoma. The DBA/2J mice developed 
glaucomatous characteristics, as IOP increased starting around 6 months of age [26]. Thus, 
we monitored IOP changes in both experimental and the fellow eyes after MSC 
transplantation as time progressed (Table 1). IOP was recorded at 2, 4, and 7 weeks post 
transplant on the DBA/2J mice. At 2 weeks post transplant (PT), the IOP of OS that received 
EBSS injection (16.11 ± 1.933 mmHg) was significantly higher than that for OD (12.11 ± 
1.124 mmHg) (P value < 0.05, paired t-test). However, all the other groups that received 
MSC transplants did not show significant differences of IOP between treated and untreated 
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eyes (P value＞0.05, paired t-test). Also, IOP changes at 4 and 7 weeks PT were not 
significant between OS and OD (P value＞0.05, paired t-test).  
Overall, we found a decreasing pattern of IOP in the eyes of the injection groups compared to 
that of untreated eyes during the 7 weeks following injection. Also, there was a transient 
increase of IOP in OS, following EBSS injection, at 2 weeks PT.  
 
Assessment of functional RGCs 
The RGC function of DBA/2J mice was evaluated, using pattern electroretinogram 
(PERG) after MSC transplantation (Table 2). The functional recordings were performed at 2, 
4, and 7 weeks PT along with IOP measurements. The amplitudes (P50-N95) ranged from 3 
to 8 µV, in general, and no significant differences were found between OS and OD. Only one 
group, eyes with EBSS injection at 4 weeks PT, showed significantly reduced amplitude 
compared with the fellow eyes; OS (4.158 ± 0.850 µV) and OD (7.435 ± 1.013 µV) (P value 
<0.05, paired t-test). In addition to the amplitude, latency (P50) was also analyzed. No 
significant differences were found between the eyes at the time points examined (data not 
shown).  
Overall, PERG amplitude during the early time points after injection did not show 
statistically different changes for any of the conditions, except EBSS injected group at 2 
weeks PT. OS with EBSS injection at the time point showed a transient decrease of 
amplitude, compared to that of fellow eyes. 
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Survival of transplanted MSCs in adult DBA/2J mice 
We examined the capacity of MSCs to survive in vivo, following intraocular 
transplantation into the adult retina of DBA/2J mice. Based on green fluorescent protein 
(GFP) expression, we found MSCs survived in the host retina up to 16 weeks PT. 
Representative images are shown in Figure 1. Many GFP-MSCs at 3 weeks PT (Figure 1; 
upper panel) and GDNF/BDNF-MSCs at 2 weeks PT (Figure 1; bottom panel) were located 
along the posterior segment of the retina. No MSC integration into the host retina was 
observed at the time-points examined.  
We observed considerable variability in MSC survival between individuals in the 
same MSC transplant group. Also, the survival ability appeared to vary among the different 
MSC populations (Table 3). GFP- and BDNF-MSCs were detected after four months PT, 
while GDNF/BDNF-MSCs were detected up to three months PT. Based on GFP-expression, 
we detected no GDNF-MSCs surviving in the host retinas at any of the time points examined. 
Mice, receiving EBSS injection (N = 6), were not included in Table 3.  
 
Qualitative analysis of retinal structure of the host retinas after MSC transplantation 
The initiation and progression of glaucoma can be monitored by histological 
examinations of the retina. Thus, we performed a qualitative analysis to examine phenotypic 
changes on host retinas after MSC transplantation. We found a large proportion of the eyes 
receiving GDNF-MSCs showed reduced glial activation,  represented by GFAP- and Iba1-IR, 
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compared with the fellow eyes (Figure 2). Such a reduction of activated glia was not 
prominent in those eyes in the other MSC transplant groups. Along with changes in glial cell 
activation, we also examined possible retinal cell proliferation. Using an antibody directed 
against phospho-histone H3 (pH3-IR), we detected little to no cell proliferation (pH3-IR) in 
the host retinas at all time points examined.  
 
Assessment of retinal layer thickness 
We evaluated whether MSC transplantation would preserve retinal architecture as 
DBA/2J mice aged. In this analysis we measured the thickness of both inner and outer retina 
as well as the whole retinal layers for both OS and OD at 16 weeks PT (Fig. 3). Our results 
showed that MSC-injected OS showed a pattern of increased thickness of the inner retina 
(NFL + GCL + IPL) on both central and peripheral retinas than for the fellow eyes (Fig. 3A). 
However, the pattern of increased thickness in OS was not observed on the outer retina 
(OPL+ONL) (Fig. 3B). For the inner retina, the central region in GDNF/BDNF-MSC 
injected OS retained significantly thicker layer than the fellow eye (OS: 17.62 ± 3.94 µm vs. 
OD: 9.69 ± 1.39 µm; N = 2 - 3, P = 0.024, paired t-test). 
When analyzing the thickness of whole retinal layers, there was no statistical 
difference between OS and OD for all the injection groups (Fig. 3C; P value ＞ 0.05, paired 
t-test). We also analyzed changes of the ratio of inner and outer retinal portion to the whole 
retinal layers. The proportional thickness of the inner and outer retinas was not significantly 
different between OS and OD in any groups examined (Fig. 3D; P value ＞ 0.05, paired t-
test). Also, peripheral retinas did not show significant changes in their proportions (Fig. 3E).  
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Our results suggest that GDNF/BDNF-MSCs contributed to the preservation of the host inner 
retina in aging DBA/2J mice. 
Changes of retinal ganglion cells and choline acetyltransferase (ChAT)-IR amacrine 
cells in the host retina 
We assessed whether transplanted MSCs played a neuroprotective role on the RGC survival 
as well as a subpopulation of amacrine cells in the host retina of aging DBA/2J mice. We 
examined the number of NeuN-IR cells in the ganglion cell layer (GCL) and ChAT-IR cells 
in the GCL and INL to see whether RGC survival and ChAT-IR amacrine cells, respectively, 
was influenced by MSC transplantation. Firstly, there was no noticeable decrease on the 
numbers of NeuN- or ChAT-IR cells between 12 and 16 weeks post transplant (PT) (data not 
shown). Also, no significant difference was found on the proportions of both NeuN- and 
ChAT-IR cells between OS and OD in all groups (Fig. 4). However, there was a trend 
towards neuroprotection of NeuN-IR cells in the GCL by GDNF- and GDNF/BDNF-MSCs 
at both 12 and 16 weeks PT.   
 
Discussion 
In the studies presented here, we have demonstrated that engineered MSCs are 
capable of surviving in the adult retina of DBA/2J mice for a relatively long period of time. 
MSCs survive up to 4 months after intraocular transplantation into the host retina without 
immune suppression. To our knowledge, this is the first study implementing MSC 
transplantation and investigating possible benefits of MSC survival in the DBA/2J retina. We 
modified MSCs genetically by performing lentiviral infection for genes of interest. MSCs 
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were engineered to produce and secrete BDNF and/or GDNF together with GFP using 
lentiviral vectors. MSCs were easily detectable, due to an endogenous expression of GFP. 
Four different types of MSCs were generated and used for our transplant study- GFP-, 
BDNF-, GDNF-, and GDNF/BDNF-MSCs. We observed differences in cell survival between 
the different MSC types. Unexpectedly, no GDNF-MSCs were detected in the host retina at 
any of the time points examined in this study. We can assume that GDNF, along with 
allografts, activated the immune system in the host retina and resulted in the poor survival 
rate for GDNF-MSCs [27]. In contrast, GFP- and BDNF-MSCs survived until 16 weeks PT 
in the host retinas. GDNF/BDNF-MSCs were detected until 12 weeks PT, but not at 16 
weeks PT.  
To evaluate physiological and functional changes of glaucomatous eyes, IOP and 
PERG amplitude were monitored. Left eye (OS- oculus sinister) received the transplants, and 
right eye (OD- oculus dexter) served as an internal, fellow control eye. During the early time 
points following MSC transplantation (7 weeks post transplant), we found some changes of 
IOP and PERG amplitude which were statistically significant between OS and OD. However, 
such changes appeared to be a transient phenomenon, possibly resulting from the injection 
procedures.  
The PERG recordings were conducted up to seven weeks following MSC transplants. 
Consistent PERG recordings were not possible beyond that time point due to corneal 
calcification and extensive corneal vascularization as DBA/2J mice age [28]. Large 
variations of PERG amplitudes at 7 weeks were attributed to such corneal problems and this 
also resulted in decreased sample sizes. Based on the physiological and functional 
assessments, there was neither noticeable neuroprotection nor deleterious effects following 
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an intraocular injection during the early time points by 7 weeks PT.    
 Following physiological and functional assessments, the influence of MSC 
transplant on the retina was examined by histological methods. We found no or little dividing 
cells, revealed by pH3-IR, exist in the host retina at all time points examined. This result 
suggests no vitreous hemorrhage and retinal detachment occurred following our injection 
[29-31].  
We also showed transplanted MSCs played a potential role in alleviating glial (Iba1- 
and GFAP-IR) activation. It has been suggested that microglial activation is a potential 
contributor to the onset or progression of glaucoma in DBA/2J mice [23]. Other studies have 
also revealed a relationship of microglia with axonal integrity and transport. Activated 
microglia obstruct axonal transport of synaptic vesicle precursors and microglial activation 
can induce neurite beading, which precedes neuronal death [32-34]. In addition, an elevated 
expression of GFAP in Müller cells was found in the glaucomatous retina, indicating the 
contribution of Müller cells to the pathological processes [35, 36]. Thus, our results suggest 
that the reduction of glial activation resulted from neuroprotective roles of transplanted 
MSCs in vivo.   
The influence of transplanted MSCs on the axons and astrocytes in the glial lamina 
of optic nerves has also been investigated (not presented here). Our results may reveal that 
neurotrophic factor-secreting MSCs contribute to the rescue of light and/or heavy 
neurofilaments, and to the maintaining of axonal transport and integrity. It has been reported 
that the heavy neurofilament (NFH) isoform, but not the light neurofilament (NFL) isoform, 
are decreased in the lamina cribrosa and postlaminar regions in pig eyes with elevated IOP 
[37]. A study in DBA/2J mice demonstrated that immunoreactivity for both NFH and NFL 
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was notably reduced in the optic nerve in the aging mice [16]. In addition, previous studies 
have reported reactive astrocytes in glaucomatous eyes. Reactive astrocytes were observed in 
glaucomatous optic nerve head, showing thick and enlarged processes [38]. Also, there was 
about a three-times increase in the number of astrocytes in the optic nerves of old DBA/2J 
mice [24].  
The survival of RGCs in the retina is another crucial factor, since the number of 
RGCs decreased significantly at around 13 months of age, when examined by retrograde 
tracers [16]. In addition to RGCs, subpopulation of amacrines (Cholinergic (ChAT) and 
GABAergic (GABA) amacrine cells) also showed significantly decreased numbers in 
DBA/2J mice compared to that of B6 mice [39]. Surprisingly, about 60% of cells in the GCL 
are displaced amacrine cells in the mouse retina [40]. In the retina of DBA/2J mice, 3.6% of 
NeuN-IR cells were ChAT-IR displaced amacrines at 3 months of age and 16.2%  were 
ChAT-IR amacrine cells at 12 and 18 month of age [16].  
Although we did not observe significant differences on the proportions of both 
NeuN- and ChAT-IR cells between OS and OD in all groups, there was a trend towards 
protection of NeuN-IR cells in the GCL by GDNF- and GDNF/BDNF-MSCs at both 12 and 
16 weeks PT.  
We also studied whether engineered MSCs could preserve the retinal architecture of 
the host retina. Previous studies have shown other retinal layers, in addition to GCL, are also 
impacted due to pathological processes in glaucoma. DBA/2J mice had a thinner retinal 
thickness on the OPL and IPL, as well as reduced numbers of cells in the INL and GCL, 
compared with those of B6 mice [39]. Also, synaptic ribbons of the rods disintegrated in 
aging DBA2J mice [41].  
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We discovered the recipient eyes with GDNF/BDNF-MSCs maintained significantly thicker 
proportion of the central inner retina, compared with the fellow eyes. These findings suggest 
that the combination of GDNF and BDNF may have resulted in a neuroprotective effect 
leading to a preservation of the inner part of the host central retina, but not the outer retina, 
following MSC transplantation in the aging DBA/2J mice. The significance found on only 
central retina and not the peripheral retina was possibly due to the distribution of surviving 
MSCs in vivo.  
When evaluating absolute values of retinal thickness, we found a pattern of increased 
thickness of the OS inner retina (NFL + GCL + IPL) on both central and peripheral regions, 
compared with the fellow eyes, although the differences were not statistically different. For 
the thickness of whole retinal layers, OS from GDNF-MSC group showed significantly lower 
values (P value = 0.0464) on the central region, compared to the fellow eyes. It is possible 
that the OS (transplanted eyes) were undergoing a more rapid degeneration compared with 
the fellow, control eyes, and that any GDNF released from MSCs could not be delivered to 
the outer retina efficiently to prevent them from undergoing rapid degeneration. 
Possible reasons for neuroprotective effects on the inner retina, but not on the outer retina, 
may be partly attributed to the localization of neurotrophic factor receptors within the inner 
retina. The expression of TrkB, a BDNF receptor, is expressed in majority of RGCs, 
amacrines, and at the vitreal border of the INL in the vertebrate retina [42]. For GDNF 
receptors, Ret is expressed in horizontal, amacrine, and RGCs and not in photoreceptors or 
Müller cells. GFRα1 expression is found in horizontal, amacrine, and RGCs. GFRα2 is 
localized in amacrine and RGCs,in the mouse retina [43]. As a future study, analyzing the 
retinal thickness of young D2 and the same age of B6 mice, as control groups, would be 
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useful for comparison. Also, we found a trend that GDNF-secreting MSCs showed a 
potential neuroprotection on the host retina, although we could not detect the cells in the host 
eyes for a sustained period of time following transplantation. That possibly suggests that a 
burst release of GDNF during the early period of time following transplantation resulted in 
neuroprotection on the host retina. 
Taken together, our results suggest the transplanted MSCs are potential cellular 
vehicles to survive for a long-term period in the glaucomatous retinas. Also, trends in the 
data suggest transplantation of MSCs, mostly secreting both BDNF and GDNF, is beneficial 
to the preservation of the host inner retina as well as retinal ganglion cells.  
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Figure Legends  
Table 1. Measurement of IOP changes recorded at 2, 4, and 7 weeks post transplant on 
DBA/2J mice following MSC transplantation. Significant differences of IOP values between 
control and experimental eyes are indicated with an asterisk (*); (1) OS vs. OD in EBSS 
group at 2 weeks post injection, (2) non-treated control vs. injection groups at 2 weeks post 
transplant (PT), and (3) non-treated control vs. injection groups at 7 weeks PT. Pattern of 
decreasing IOP in the injection group compared with the fellow eyes, as time progressed. 
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(Numbers: Average ± S.E.M.; *P value <0.05, paired t-test; Abbreviation: OS-oculus 
sinister, left eye; OD-oculus dexter, right eye) 
 
Table 2. Recordings of PERG amplitudes (P50-N95) performed at 2, 4, and 7 weeks PT in 
DBA/2J mice following MSC transplantation. Significant differences of amplitude between 
control and experimental eyes are indicated with an asterisk (*); between the OS and OD in 
EBSS group at 4 weeks PT. In addition to amplitude, latency (P50) also analyzed and no 
significant differences were found between the eyes (data not shown). (Numbers: Average ± 
S.E.M.; *P value <0.05, paired t-test) 
 
Table 3. Survival of transplanted MSCs in adult DBA/2J host retina. 
Numbers of mice with transplanted MSCs at different time points of tissue collection are 
summarized. Transplanted MSCs survived up to 16 weeks PT in the adult DBA/2J retinas. 
Different survival ratio was observed between individuals in the same MSC group as well as 
between different MSC populations. No GDNF MSCs survived in host retinas at any time 
point examined. Mice receiving EBSS injection (N = 6) not included in this table. Numbers 
in bold type mean number of mice with surviving MSCs out of the total number of mice in 
the group.   
 
Figure 1. Survival of transplanted MSCs in adult DBA/2J host retina. Many GFP-MSCs at 3 
weeks PT (A) and GDNF/BDNF-MSCs at 2 weeks PT (B) found along the posterior segment 
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of host retina. MSCs retained a strong expression of GFP and often localized along the inside 
of the host retina. Abbreviations: ONH-optic nerve head; DAPI: 4’, 6-diamidino-2-
phenylindole, dilactate; DIC: differential interference contrast. Scale bars are 50 microns. 
 
Figure 2. Potential role of MSCs on the reduction of glial activation after MSC 
transplantation into host retina. Some eyes, that received MSCs, showed relatively decreased 
level of glial activation, compared with the fellow eyes. (A and B) Retinas stained with 
GFAP antibody. Eyes received GDNF-MSCs and collected at 4 weeks PT shown. (C and D) 
Retinas stained with Iba1 antibody. Eyes received GDNF-MSCs and collected at 12 weeks 
PT shown as examples.  
A and C: OS, B and D: OD. Scale bars are 50 microns. Abbreviations: ONL- outer nuclear 
layer; INL- inner nuclear layer; IPL- inner plexiform layer; GCL- ganglion cell layer. 
 
Figure 3. Assessment of retinal layer thickness. The thickness of both inner and outer retina 
as well as the whole retinal layers were quantified for both OS and OD at 16 weeks PT. (A) 
The thickness of the inner retina (NFL + GCL + IPL): OS, which received an MSC injection, 
showed a pattern of increased thickness of the inner retina on both central and peripheral 
retinas, compared with the fellow eyes. The central region in GDNF/BDNF-MSC injected 
OS showed a significant difference on the thickness between OS and OD (OS: 17.62 ± 3.94 
µm vs. OD: 9.69 ± 1.39 µm; P = 0.024, paired t-test). (B) The thickness of the outer retina 
(OPL+ONL): The increased pattern of the thickness in OS was not observed on the outer 
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retina. (C) The thickness of whole retinal layers: None of the injection groups showed 
statistical differences of the thickness between OS and OD.  
(D and E) The ratio of inner and outer retinal portion to the whole retinal layers:. The 
proportional thickness of the inner and outer retinas was not significantly different between 
OS and OD in any groups examined. Also, peripheral retinas did not show significant 
changes of the proportions.  
 
Figure 4. RGC survival in the DBA/2J host retina following MSC transplantation. 
Percentages of NeuN- and ChAT-IR cells in the host GCL were assessed at 12 weeks- (A) 
and 16 weeks-(B) PT. No significant difference was found on the proportions of both NeuN- 
and ChAT-IR cells between OS and OD in all groups. However, there was a trend towards 
protecting NeuN-IR cells in the GCL by GDNF- and GDNF/BDNF-MSCs at both 12 and 16 
weeks PT. 
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Tables and Figures 
Table 1. Measurement of IOP changes recorded at 2, 4, and 7 weeks post transplant on the 
DBA/2J mice following MSC transplantation. 
Weeks post 
transplant 
2   4   7   
Transplant group OS OD OS OD OS OD 
EBSS 16.11 * 
(± 1.933) 
12.11 * 
(± 1.124) 
12.13 
(± 1.922) 
11.88 
(± 1.846) 
14.33 
(± 2.418) 
17.67 
(± 1.563) 
GFP MSC 19.27 
(± 2.141) 
15.36 
(± 1.416) 
15.6 
(± 2.495) 
18.2 
(± 2.004) 
10.44 
(± 0.93) 
12.56 
(± 1.435) 
BDNF MSC 18.36 
(± 2.674) 
13.27 
(± 0.915) 
12 
(± 1.653) 
14.8 
(± 1.533) 
12.5 
(± 2.252) 
13.33 
(± 1.716) 
GDNF MSC 17.2 
(± 1.123) 
16.5 
(±1.833) 
14 
(± 2.435) 
16.38 
(± 1.752) 
12.5 
(± 1.565) 
17 
(± 3.13) 
GDNF/BDNF MSC 14.27 
(± 1.192) 
14.18 
(± 1.577) 
17.88 
(± 3.528) 
13.57 
(± 1.771) 
13.5 
(± 1.384) 
15.6 
(± 3.027) 
 
 
Table 2. Recordings of PERG amplitudes (P50-N95) performed at 2, 4, and 7 weeks post 
transplant in DBA/2J mice following MSC transplantation.  
Weeks post 
transplant 
2   4   7   
Transplant group OS OD OS OD OS OD 
EBSS 5.52 
(± 0.910) 
4.189 
(± 0.819) 
4.158 * 
(± 0.850) 
7.435 * 
(± 1.013) 
16.87 
(± 2.137) 
11 
(± 5.878) 
GFP MSC 5.132 
(± 0.964) 
3.656 
(± 0.733) 
5.585 
(± 0.988) 
6.267 
(± 1.634) 
7.247 
(± 3.587) 
5.508 
(± 1.346) 
BDNF MSC 5.539 
(± 0.823) 
4.622 
(± 1.378) 
8.783 
(± 2.067) 
7.808 
(± 1.303) 
13.5 
(± 3.674) 
8.862 
(± 2.862) 
GDNF MSC 4.185 
(± 1.036) 
4.357 
(± 0.632) 
5.362 
(± 1.177) 
4.832 
(± 1.058) 
4.19 
(± 0.93) 
5.695 
(± 0.085) 
GDNF/BDNF MSC 3.735 
(± 0.609) 
4.475 
(± 0.910) 
2.94 
(± 1.61) 
4.483 
(± 1.57) 
13.71 
(± 6.047) 
2.72 
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Table 3. Survival of transplanted MSCs in the adult DBA/2J host retina.  
Transplant Groups 
Number of 
Mice 
  Weeks Post Transplant 
   < 12 12 16 
GFP MSC 9 1/2 1/3 3/4 
BDNF MSC 9 1/1 1/3 2/5 
GDNF MSC 9 0/3 0/3 0/3 
GDNF/BDNF MSC 9 2/4 2/3 0/2 
 
 
 
Figure 1. Survival of transplanted MSCs in the adult DBA/2J host retina. 
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Figure 2. Potential role of MSCs on the reduction of glial activation after MSC 
transplantation into the host retina.  
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 (A) Inner retina (GCL + NFL + IPL) 
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Figure 3. (Continued) 
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(B) Outer retina (OPL+ONL) 
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Figure 3. (Continued) 
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(C) Whole retinal layers 
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Figure 3. (Continued) 
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(D) Inner retina (GCL + NFL + IPL) 
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Figure 3. (Continued) 
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(E) Outer retina (OPL + ONL) 
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Figure 3. Assessment of retinal layer thickness 
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 (A) 12 weeks PT 
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Figure 4. (Continued) 
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(B) 16 weeks PT 
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Figure 4. RGC survival in the DBA/2J host retina following MSC transplantation. 
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Abstract  
The purpose of this preliminary study was to investigate the potential neuroprotective 
effects of BDNF-secreting MSCs on the retina of MYOC-mice. Mutations in MYOC are 
found in 3-4% of people with primary open-angle glaucoma (POAG). A transgenic mouse 
model, Tg-MYOC
Y437H
, was generated by using a human MYOC gene modified to introduce 
a point mutation. The mice are an additional model of chronic glaucoma. In vitro studies 
indicate that mutant Myocilin accumulates in the endoplasmic reticulum (ER), and results in 
ER stress and cytotoxicity on the cells of the trabecular meshwork. In vivo mechanisms that 
lead to IOP elevation in this mutant mouse are not understood yet, but such ER stress may be 
involved in the development of IOP elevation [1-3]. It has been known that BDNF functions 
as a survival factor for neurons in vitro as well as in vivo [4-9]. In addition, BDNF signaling 
is involved in the suppression of ER stress and neuronal apoptosis [10-12].  
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In this study, we employed two types of genetically modified MSCs, BDNF/GFP-
MSCs and GFP-MSCs, to deliver BDNF into the host retina via cellular vehicle. Each MSC 
populations were intravitreally injected into 8 week-old eyes of MYOC mice. Then, 
histological examinations were performed at 11.5 months post transplant (PT). Both BDNF- 
and GFP-MSCs survived up to 11.5 months PT in the adult host retina. However, 
transplanted MSCs did not significantly affect the number of surviving RGCs (NeuN-
immunoreactive), comparing the experimental and control eyes. Our immunohistochemical 
staining revealed myocilin is primarily expressed on the trabecular meshwork (TM), sclera, 
and ciliary body. When comparing the levels of myocilin protein on the TM, the recipient 
eyes displayed stronger immunoreactivity (IR) against myocilin than the fellow eyes. 
Most interestingly, to our knowledge, these results provide the first evidence that 
MSCs can survive approximately a year in the adult retina of MYOC-mice following 
intraocular transplantation. This suggests MSCs are a potential cellular vehicle to deliver 
trophic factors to the host retina for a long-term period. In addition to this preliminary study, 
further examination is required to increase our knowledge on developing therapeutic 
strategies for glaucoma.  
 
Introduction 
Of the three major types of glaucoma, primary open angle glaucoma (POAG) is the 
most common [13]. In humans, there is an inheritance factor in primary open-angle glaucoma 
(POAG) and mutations in MYOC are found in 3-4% of people with POAG [14]. Myocilin is 
a secreted glycoprotein highly expressed in the trabecular meshwork, ciliary body, sclera, 
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and iris, as well as expressed in the retina and the optic nerve head at low amounts [15]. It 
has been suggested that myocilin plays a role in the interaction of cells with the matrix, but 
the functions of myocilin are not fully understood, yet [14-17].  
As an additional transgenic model of glaucoma, myocilin (MYOC)-mutant mice have 
been developed and characterized [3, 18]. A transgenic mouse mode, Tg-MYOC
Y437H
, was 
generated by using the human MYOC gene, modified to introduce a point mutation [3]. It has 
been reported that mutant myocilin accumulates in the endoplasmic reticulum (ER), and 
results in ER stress and cytotoxicity on the cells of the TM. Such ER stress leads to the 
development of IOP elevation [1-3]. Tg-MYOC
Y437H
 mice were characterized and showed 
glaucomatous phenotypes, such as IOP elevation, axon degeneration, and death of RGCs [3].  
Neurotrophic factors have been investigated and utilized in developing strategies of 
rescuing injured/or degenerative retinas, since it is known the retrograde transport of BDNF 
was interrupted in eyes of experimental glaucoma [19, 20]. In addition, the absence of 
endogenous BDNF and NT-4/5 was shown in the superior retina and optic nerve head of 
hypertensive rat eyes during the time of RGC death [29]. It has been demonstrated that 
BDNF stimulated regrowth of RGC axons [7] and increased the survival of RGCs [8] in vivo. 
Moreover, BDNF delivered via MSCs to glaucomatous eyes with chronic ocular 
hypertension provided both functional and structural neuroprotection on the host retina and 
optic nerve [9].  
Bone marrow-derived MSCs are a potential source for stem cell-based therapy. 
Several advantages include 1) easy isolation, 2) significant plasticity, 3) no ethical concerns, 
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4) a potential autologous transplant, and 5) availability of engineering to produce a cellular 
vehicle for delivering NFs for a long-term period.  
Engineering MSCs to make cellular vehicles for neurotrophic factor delivery allows 
us to overcome challenging issues, such as sustained long-term secretion of bioactive NTs 
and repetitive injections into the eye. MSCs have shown morphological neuroprotective 
effects on the survival of RGCs/or their axons following intravitreal transplantation into the 
eyes of experimental glaucoma [21, 22]. In addition to morphological protection, functional 
rescue of the RGCs is required and is a more crucial issue to demonstrate the capacity of 
MSCs as a neuroprotectant. It appears functional deficits in RGCs precede structural 
abnormalities and cell death [23, 24].  
Therefore, the purpose of the study in this chapter is to investigate potential 
neuroprotective effects of engineered MSCs on the eyes of MYOC-mice. We performed 
histological examinations on the host retina, following MSC transplantation to assess our 
neuroprotective strategy. For the first time, we demonstrated engineered MSCs can survive 
up to a year in the adult retina of MYOC-mice without immune suppression. We quantified 
the number of surviving RGCs of the host retina to determine the potential neuroprotective 
effect of MSCs. There was no significant change of NeuN-immunoreactive (IR) cells on the 
ganglion cell layer (GCL).  
 
Materials and Methods   
Animals 
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In collaboration with the University of Iowa, 11 MYOC-mice (8-weeks old) were 
used for this transplant experiment. This transgenic mouse model (Tg-MYOCY437H) 
expresses a human MYOC gene containing the Y437H mutation, as previously described [3]. 
Mice were housed and bred at the Research Animal Facility of the University of Iowa. All 
animal studies were conducted in accordance with the Association for Research in Vision 
and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision 
Research and were approved by Iowa State University Institutional Animal Care and Use 
Committee and the University of Iowa Animal Care and Use Committee. 
 
Mouse mesenchymal stem cells (MSCs) 
Mouse MSCs isolated from the bone marrow of adult C57BL/6 mice were obtained from 
Tulane Center for Gene Therapy (New Orleans, LA) and maintained as an adherent cell line 
in Iscove's Modified Dulbecco's Medium (IMDM; 12440–046; Invitrogen, Carlsbad, CA) 
containing 10% hybridoma-qualified FBS (Cat #-SH30396.03, Hyclone, Logan, UT), 10% 
equine serum (Cat #- SH3007403, Hyclone, Logan, UT), 2 mM L-glutamine, and 10,000 
U/mL penicillin, 10,000 µg/mL streptomycin. When cultures reached 70–80% confluence, 
MSCs were gently detached from the flask using a 0.05% trypsin and 0.1% EDTA solution 
(Invitrogen) and were pelleted at 500 rpm for 5 minutes. MSCs were subsequently plated into 
75 flasks at low confluence. Cultures were maintained by supplementing the flask with fresh 
medium every other day. 
Engineering MSCs Ex Vivo with lentiviral vectors 
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MSCs were infected using lentiviral vectors to engineer them to secrete brain-
derived neurotrophic factor (BDNF; human cDNA) as previously reported [6]. Briefly, 
MSCs were plated in six-well plates at a density of 10,000 cells per well and were allowed to 
adhere for a day. After adhering to the plate, the growth medium in each well was replaced 
with IMDM, containing 2% FBS and 12 µg/mL Sequa-brene (152667; Sigma-Aldrich, St. 
Louis, MO). Each lentiviral vector’s encoding BDNF (LV-BDNF; CMV-BDNF-IRES-GFP) 
and green fluorescence protein (GFP, LV-GFP; CMV-GFP) were added separately to MSCs 
at a multiplicity of infection (MOI) of 1,000 for each vector. Media containing viral particles 
were removed after 8 hours of incubation and fresh growth medium was added. When 
confluence reached 70–80%, MSCs were transferred to a flask for subsequent maintenance. 
Subcultures were performed as described above. MSCs, that expressed strong green 
fluorescence, were collected by fluorescence-activated cell sorting (FACS). To sort MSCs by 
FACS, BDNF-MSCs were collected in a 15 ml tube. The sample tube contained 3 to 5 
million MSCs in 0.5 ml culture media. Then, MSCs with strong green fluorescence were 
collected in a catch tube containing 1 ml FBS.  
 
Cell transplantation 
To perform an intraocular injection, MSCs were collected by gently detaching with a 
0.05% trypsin and 0.1% EDTA solution, and pelleted at 500 rpm for 5 minutes. The 
supernatant media was removed and the pellet was resuspended with Earle's Balanced Salt 
Solution (EBSS) at a concentration of 50,000 cells per µl. A beveled glass microelectrode 
attached to a Hamilton syringe was utilized to inject 2 µl of MSC cell suspension 
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intravitreally. The left eye served as an experimental group and the right eye was the control 
group. Two different groups of injections were included: (1) BDNF-GFP-MSCs (N = 6) and 
(2) GFP-MSCs (N = 5) as a cellular control.     
 
Tissue preparation and immunohistochemistry 
Ocular tissues were collected at 11.5 months post transplant (PT). The mice were 
deeply anesthetized with ketamine/xylazine and quickly euthanized by cervical dislocation. 
The eye globes were fixed with 4% paraformaldehyde (pH 7.4) and cryoprotected in 30% 
sucrose and embedded in an OCT compound (Tissue-Tek, Torrance, CA). Frozen sections 
were prepared in 16 µm thickness and examined for immunohistochemistry analysis. A panel 
of primary antibodies was used for histological examinations. Tissue sections were incubated 
in a blocking solution containing 5% normal donkey serum and 0.2% Triton X-100 (Fisher 
Scientific), followed by incubation with primary antibodies overnight at 4°C. Primary 
antibodies used were anti-GFAP (1:500, Fisher Scientific, Pittsburgh, PA), anti-Iba1 (1:400, 
Wako, Richmond, VA), anti-GFP (1:400, Millipore, Billerica, Massachusetts), and anti-
phospho-histone H3 (pH3) (1:1,000, Abcam, Cambridge, MA), After rinsing in PBS, tissue 
sections were incubated in the secondary antibodies conjugated to Cy3 (1:500, Jackson 
ImmunoResearch, West Grove, PA), FITC (1:500, company), or Cy5 (1:500, company). Cell 
nuclei were stained with 4’, 6-diamidino-2-phenylindole, dilactate (DAPI), diluted at 1:2,000 
in PBS, and applied for 30 minutes. Preparations were rinsed and then covered with 
coverglass using an antifade mounting medium (Gel Mount; Biomeda Corp., Foster City, 
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CA). Negative controls were performed in parallel by omission of the primary antibodies. No 
antibody labeling was observed in the controls.  
 
RGC counting 
To quantify the number of surviving RGCs in the retina, we assessed the number of 
NeuN-IR cells in the GCL. NeuN is a nuclear protein that identifies mature neurons. It is 
reported that most NeuN-IR cells on the GCL are RGCs, with a small proportion of choline 
acetyltransferase (ChAT)-IR displaced amamcrine cells [24]. Both OS and OD from 11 mice 
were analyzed. NeuN-IR cells were manually counted, using ImageJ software. Three medial 
cross-sections from each eye were analyzed and three separate areas in each retinal section 
were assessed: center, periphery1, and periphery2. Imaging on the peripheral regions was 
performed from the very end of peripheries on each side. Analysis was performed in a 
masked manner. 
 
Imaging and statistics 
Retinal images were photographed using an upright fluorescence microscope (Nikon 
Microphot FXA) equipped with a Retiga 2000R digital camera controlled by QCapture 
software (QImaging, Surrey, British Columbia, Canada). Figure plates were prepared using 
Photoshop CS2. Data were reported as means ± S.E.M. Statistical analyses were performed 
by using Student’s t-test, paired t-test, and one-way ANOVA (GraphPad, San Diego, CA). P
＜0.05 was considered significant. 
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Results  
Long-term survival of MSCs in adult eyes of MYOC-mice  
We studied myocilin-mutant (MYOC) mice as an additional model of experimental 
glaucoma. This model develops glaucomatous phenotypes which mimick human patients’, 
and the mice are the first transgenic model of MYOC-associated POAG [3]. In addition, this 
model does not develop iris stromal atrophy, as DBA/2J mice do. Thus, pupillometry, which 
evaluate pupillary light reflex, can be used as another fuctional method plus to 
electroretinography. Two different types of MSCs (BDNF/GFP- and GFP-MSCs) were 
engineered and utilized for this study, and an intraocular injection was performed on the left 
eye only. Then, both eyes were collected at 11.5 months PT for histological examinations. 
We discovered both BDNF- and GFP-MSCs survived up to 11.5 months PT in the adult host 
retina (Figure 1 and Table 1). MSCs were found in the posterior segment of the eye and no 
integration of transplanted cells into the host retinas was observed. There was variability of 
MSC survival between mice. Some eyes retained small or large numbers of MSCs, while 
others lacked the visible green MSCs. A wilt-type mouse, C57BL/6J, was included in the 
study and a few MSCs survived in its eye as well. 
In an eye (ID 5) that contained large numbers of MSCs, we found many pH3-IR cells 
in the MSC population (image not shown). Immunoreactivity to pH3, which is a marker for 
Histone H3 phosphorylation, indicates that the cells are mitotic. However, all other OS did 
not show pH3-IR MSCs. Also, we have not observed any pH3-IR cells in the host retinas of 
all the mice examined.   
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Assessment of RGC survival after MSC transplantation  
To evaluate the survival of retinal ganglion cells in the adult MYOC-mice following 
MSC transplantation, we quantified the number of NeuN-IR cells on the GCL of the retinas 
(Figure 2). NeuN is a nuclear protein that identifies mature neurons. It is reported that most 
NeuN-IR cells on the GCL are RGCs, with a small proportion of ChAT-IR displaced 
amamcrine cells [24]. The percentage of neuronal cells on the GCL was calculated for the 
NeuN-IR cells as compared to all cell nuclei stained with DAPI. Figure 3 and Table 2 shows 
the average percentages of surviving RGCs (NeuN-IR) of OS and OD after the experiment 
period of 11.5 months. Both central and peripheral retinas are analyzed from BDNF- and 
GFP-MSC transplant groups. No significant difference was found between experimental and 
control eyes, although there was a trend that showed a greater number of surviving NeuN-IR 
cells in the control eyes than in the treated eyes. Approximately 30 to 50% of the cells are 
NeuN-IR on the GCL of MYOC-mice retinas. No significant difference was shown between 
the percentages of neuronal cells in the GFP-MSC condition when compared to the BDNF-
MSC condition.  
 
Expression of myocilin on the ocular tissues  
Since this transgenic model of glaucoma was generated by the mutation of MYOC 
gene, which, in turn, results in the accumulation of mutant myocilin protein on the trabecular 
meshwork (TM), we investigated whether MSC transplantation would influence the 
expression of myocilin protein on the TM. We performed immunohistochemistry using a 
polyclonal rabbit antibody to mouse Myoc [25] and the immunoreactivity against myocilin 
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was shown primarily on the TM, sclera, and ciliary body. In many cases, myocilin expression 
was upregulated on the TM region in the OS, compared to the fellow eyes (Figure 4).   
 
Discussion 
In this preliminary study we have demonstrated that engineered MSCs are capable of 
surviving in the adult retina of MYOC-mice for approximately one year following 
intravitreal transplant. To our knowledge, this is the first study implementing MSC 
transplantation and investigating possible benefits of MSC survival in the MYOC-mice retina. 
We provided the first evidence that demonstrates the longest time for MSC survival, 
following intraocular transplantation into the eyes of MYOC-mice. MSCs, visualized by 
green fluorescence, were found in the eyes of both transgenic and wild-type mice at 11.5 
months-PT. Although we observed a larger number of cases for GFP-MSC survival than 
BDNF-MSC’s, it is highly possible that strong GFP expression on the GFP-MSCs allowed us 
to detect them easier than BDNF-MSCs, which showed little or no detectable GFP.  
To date, no studies have demonstrated that transplanted MSCs survive as long in the 
adult host eye. In a similar study on the rats with experimental glaucoma, MSCs transplanted 
intravitreally only survived for five weeks [21]. When comparing these results with other 
studies, our findings of MSC survival up to 1 year brings about an interest in finding the 
reason for the long life of MSCs. 
We observed no dividing cells (pH3-IR) in the host retinas, which may suggest no 
vitreous hemorrhage and retinal detachment occurred following our injection. Only one OS 
(ID 5), which contained a number of GFP-MSCs, showed many pH3-IR cells in the MSC 
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population. That indicates some of the transplanted MSCs were still capable of proliferating 
in the host retina at 11.5 months post transplant. This could be possible, as the eye is an 
immune privileged site and provides tolerant environments for cell transplant [28].  
The survival of RGCs in the retina is a crucial factor and it was reported that 
Tyr437His mutant mice showed 20% loss of RGCs in the peripheral retina at 18 months of 
age, compared to that of wild-type littermates. However, no significant RGC loss was found 
in the central retina [18]. From the analysis of NeuN-IR cells on the host GCL, we 
determined no significant difference between the percentages of surviving RGCs at both 
central and peripheral retinas in either transplant group as compared to the control group. A 
previous study [9] demonstrated BDNF-secreting MSCs transplanted into glaucomatous eyes 
of rats resulted in both functional and morphological preservation of the host retina, as 
compared to the eyes with GFP-MSC transplant. We could expect the rescue effects of 
BDNF-secreting MSCs on the RGCs as well as TM cells. TrkB, a BDNF receptor, is 
expressed in majority of RGCs [30] and TM cells [31]. Additionally, exogenous BDNF 
suppresses ER stress, which is a possible mechanism of TM cell death in MYOC-mice, and 
results in neuronal protection [32, 33]. For our results, we cannot exclude the possibility that 
lack of detectable neuroprotection could be caused by a small sample size and/or lack of 
examinations at different time-points before 11.5 months PT.  
We discovered an increased level of glial activation, examined by GFAP- and Iba1-
IR, in the retinas that received MSC transplant compared to the fellow eyes (data not shown). 
This may indicate injection of MSCs does cause an effect on the host retina, possibly because 
of the invasive nature of introducing a foreign substance into the eye. It has been known that 
the microglia function either compromises graft viability or promotes graft survival by 
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secreting trophic factors [26]. This still requires further investigation on the roles of 
microglia in retinal transplants, so we can improve our strategy for increasing graft viability. 
Other studies have reported that mutant myocilin is accumulated in the TM of 
MYOC-mice and such accumulations were reduced by a chemical treatment—phenylbutyric 
acid [3, 27]. In our study, we found TM of the recipient eyes showed stronger IR against 
myocilin, compared to the fellow eyes. This possibly indicates transplanted MSCs affected 
the eye to result in increased secretion or an accumulation of myocilin on the TM, which was 
an unexpected result. Further studies would be required to understand in vivo mechanisms 
that resulted in this phenomenon. 
In conclusion, our results provide the first evidence that MSCs could survive a year 
in the adult retina of MYOC-mice, following intraocular transplantation. This suggests MSCs 
are a potential cellular vehicle to deliver trophic factors to the host retina for a long-term 
period. In addition to this preliminary study, further examinations are required to increase our 
knowledge on developing therapeutic strategies for glaucoma.  
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Figure Legends  
Table 1. A summary table showing the survival of transplanted MSCs in the retina of adult 
MYOC-mice.  (N: none, +: a few, ++: some, +++: many, ++++: a lot)  
 
Table 2. Survival of retinal ganglion cells (NeuN-IR) in the adult MYOC-mice retina. 
Numerical values of the RGC survival are shown.  
 
Figure 1. Survival of transplanted MSCs in the host retina of MYOC-mouse. A retinal 
section with a number of GFP-MSCs is shown. The eye from mouse  ID 5 received GFP-
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MSCs and retinal tissues were collected at 11.5 months PT. Scale bar = 100 µm. 
Abbreviation: RPE- retinal pigment epithelium. 
 
Figure 2. Representative images showing NeuN-IR cells in the GCL of the host retina. Both 
peripheral regions as well as central retina were analyzed.  Red: NeuN-IR cells on the GCL; 
Blue: nuclei stained with DAPI. Scale bar = 100 µm. 
Abbreviations: ONL- outer nuclear layer; INL- inner nuclear layer; IPL- inner plexiform 
layer; GCL- ganglion cell layer.   
Figure 3. Survival of retinal ganglion cells (NeuN-IR) in the adult MYOC-mice retina. 
The change of RGC number is quantified by counting NeuN-IR cells on the ganglion cell 
layer of the retinas. Graphs show the average percentage of surviving NeuN-IR cells after the 
experiment period of 11.5 months for both OS and OD. Central and both peripheral retinas 
are analyzed and no significant difference was found between the control and treatment eyes. 
Approximately 30 to 50 % of the cells are NeuN-IR on the GCL of MYOC-mice retinas. The 
p values for the MSC injection group as compared to controls are > 0.05. Error bars are 
standard error. 
 
Figure 4. Upregulated expression of myocilin protein on the trabecular meshwork (TM) after 
MSC transplantation. The expression of myocilin was compared on the TM between the 
experimental and fellow eyes. Increased immunoreactivity of myocilin (red) are found on the 
TM (indicated by arrow heads) of OS, compared to that of OD.  
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A – C: OD, D – F: OS; Abbreviations: R- retina, CB- ciliary body, TM- trabecular 
meshwork; Scale bars are 100 microns. 
 
Tables and Figures  
Table 1. 
Transplant 
Mouse ID Mouse Strain Number of surviving MSCs 
GFP MSC 3 C57BL/6J + 
 1 MYOC + 
 4 MYOC N 
 5 MYOC ++++ 
  6 MYOC ++ 
BDNF MSC 2 MYOC N  
 7 MYOC N 
 8 MYOC + 
 9 MYOC + 
 10 MYOC N 
  11 MYOC N 
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Table 2. Survival of NeuN-IR cells in the adult MYOC-mice retina. 
(A) Transplant of BDNF-MSCs 
NeuN-IR   OS     OD   
  
Periphery 
1 
Periphery 
2 
Central 
Periphery 
1 
Periphery 
2 
Central 
Number of mice 4 4 4 5 5 5 
Mean 31.96 31.16 39.82 39.71 45.93 42.83 
Standard Error 3.1 3.335 6.032 6.281 6.205 8.65 
 
 
(B) Transplant of GFP-MSCs 
NeuN-IR   OS     OD   
  
Periphery 
1 
Periphery 
2 
Central 
Periphery 
1 
Periphery 
2 
Central 
Number of mice 1 1 1 4 4 4 
Mean 36.62 35.23 42.18 55.13 48.04 51.74 
Standard Error NA NA NA 5.131 4.171 2.588 
(NA: not applicable) 
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Figure 1. Survival of transplanted MSCs in the host retina of MYOC-mouse. 
 
 
Figure 2. Representative images showing NeuN-IR cells in the GCL of the host retina. 
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Figure 3. Survival of retinal ganglion cells (NeuN-IR) in the adult MYOC-mice retina. 
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Figure 4. Upregulated expression of myocilin protein on the trabecular meshwork after MSC 
transplantation. 
 
 
 
 
 
 
 
 
 174 
CHAPTER 6: GENERAL CONCLUSIONS 
Firstly, the studies presented in this dissertation are the first to characterize bone marrow 
MSCs from Brown Norway rats and demonstrate their capability to promote neurite 
outgrowth from neuronal AHPCs and stimulate oligodendrocyte differentiation. Secondly, 
the studies describe, for the first time, the potential of genetically modified MSCs as a 
cellular vehicle of neurotrophic factors for the eye of transgenic mouse models of glaucoma. 
Our strategy of cell-based therapy consists of in vitro studies, engineering MSCs to make 
them secrete BDNF and/or GDNF, and the following in vivo studies, perform an intraocular 
transplantation into the eyes of two different models of transgenic mice (DBA/2J and 
Myocilin-mutant mice). 
These studies provide a new resource of bone marrow MSCs and this broadens the 
opportunity of MSC utilization in a variety of research fields, including neurodegenerative 
diseases and injuries. Also, our in vivo studies provide a clue to the development of long-
term therapeutic strategy for glaucomatous retinas.  
 
We have made a number of important observations in these studies, including: 
1. Mesenchymal stem cells (MSCs), derived from the bone marrow of Brown Norway rats, 
can be easily isolated and expanded in culture for a sustained period of time. MSCs were 
healthy and showed stable and consistent growth rate. 
2. Rat MSCs were capable of stimulating neurite outgrowth from adult hippocampal 
progenitor cells (AHPCs). Also, MSCs promoted morphological differentiation of 
oligodendrocytic AHPCs, examined by co-culture. 
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3. We successfully engineered mouse MSCs and they secrete increased amount of bioactive 
Brain-derived neurotrophic factor (BDNF) and/or Glial cell-derived neurotrophic factor 
(GDNF). 
4. We have demonstrated that engineered mouse MSCs could survive up to 4 months post 
transplant (PT) in the adult host retinas of DBA/2J mice. 
5. We also have shown that engineered MSCs could survive up to 1 year post transplant in 
the adult host retinas of Myocilin-mutant mice.   
6. We have found that a potential role of MSCs on the reduction of glial activation after MSC 
transplantation into the DBA/2J host retina. 
7. We have found that potential neuroprotection, following MSC transplantation, on the 
retinal ganglion cells (RGCs) in the retina, RGC axons in the optic nerve, and retinal 
architecture on the inner retina.  
The final conclusion of this dissertation is that bone marrow derived MSCs are a potent cell 
population capable of promoting neuronal and oligodendrocytic differentiation from brain 
progenitors. Furthermore, genetically modified MSCs, which secrete BDNF and/or GDNF, 
have potential to provide neuroprotection on degenerating host retinas and optic nerves.   
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RECOMMENDATIONS FOR FUTURE RESEARCH 
The studies presented in this dissertation provide very important evidence showing the 
capacity of bone marrow-derived MSCs in vitro as well as in vivo. 
Our in vivo studies using hereditary glaucoma models, that mimic human glaucoma, and 
MSCs, as a potential vehicle of neurotrophic factors, provide a good step to develop 
strategies of cell-based therapy for human glaucoma. Future studies to be performed in these 
mouse models would be detection of neurotrophic factors in vivo after MSC transplantation. 
Using very sensitive detection technique, such as High-performance liquid chromatography 
(HPLC) or western blots would allow us to detect even very small amount of BDNF or 
GDNF from the vitreous humor of the host eyes. Additionally, performing behavioral tests 
would provide more convincing evidence demonstrating successful neuroprotection. Possible 
behavioral tests that are available for rodents include 1) Morris water maze and swim task, 
which test central vision, and 2) Rotarod measurements, which test vision and vestibulomotor 
function, and 3) assessment of optokinetic response, which evaluate visual acuity and 
contrast sensitivity. Also, investigation of other potential neuroprotective proteins, such as 
NT3, NT4, NGF, and CNTF, and the combination of the factors would be very useful. In our 
in vivo studies, increasing sample size per each transplant group will be required to evaluate 
the significance of the effects following MSC transplantation.  
Since physiological phenomena in vivo are very complex, we do not know which types of 
retinal cells respond and which signaling pathways are activated or inactivated in response to 
BDNF, GDNF, or the combination of both factors in the host retinas. Further experiments to 
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reveal changes in molecular aspects will be required for better understanding of 
neuroprotection.  
Considering of clinically more relevant trials, the next step in the series of these studies 
would be to investigate the effectiveness of MSC transplant in large animal models, such as 
cat, dog, or pig. These animals would be more appropriate to study human glaucoma, than 
rodents. They have a larger size of eyes than rodents’ and also they allow us to examine our 
strategy for a longer period of time, up to years. Outcome from our studies will be supportive 
to develop clinical therapies in the humans.   
 
 
 
 
 
 
